<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cik0002065779="http://cik0002065779/20260331"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cik0002065779-20260331.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-11</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-02</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-05</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-02</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cik0002065779:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinaryShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cik0002065779:ConversionOfClassBToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-01_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="AsOf2022-07-01_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-06</endDate>
        </period>
    </context>
    <context id="From2022-10-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-02-11</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsAndUSDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-03-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-03-31" id="Fact000004">0002065779</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0039"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_CommonStockMember"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      id="xdx2ixbrl0083"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-18"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AmountDueToRelatedParty
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0454"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0456"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1148"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1150"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1191"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1192"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1195"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1223"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1225"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1230"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968"
      id="xdx2ixbrl1236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      id="xdx2ixbrl1237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1250"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1292"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1294"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1493"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1848"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1849"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1883"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1884"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1890"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1901"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1998"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1999"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2217"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2221"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2227"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2231"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2235"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2244"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2248"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2258"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2272"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2278"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2282"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2286"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2514"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2606"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensation1
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2631"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:U.s.DollarCoin
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2692"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:PrepaidResearchAndDevelopmentExpenses
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2915"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2919"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2939"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2945"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2956"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2957"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2964"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2966"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2971"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2972"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2982"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2983"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2988"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2995"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3010"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3012"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3017"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3018"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3019"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3027"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3028"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3029"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3030"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3034"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3041"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3060"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3077"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3108"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:PaymentForDeferredOfferingCosts
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3116"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAssumed1
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansAssumed1
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3426"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3430"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3444"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3448"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3450"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3452"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3456"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3458"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3460"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3464"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3468"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3470"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3472"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3627"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3876"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3906"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3908"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3963"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:AmendmentDescription contextRef="From2026-01-01to2026-03-31" id="Fact000010">Amendment
No. 1</dei:AmendmentDescription>
    <dei:DocumentType contextRef="From2026-01-01to2026-03-31" id="Fact000011">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-03-31" id="Fact000012">D. Boral ARC Acquisition I Corp.&#160;</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-03-31" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-03-31" id="Fact000014">42-3035215</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-03-31" id="Fact000015">10 East 53rd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-03-31" id="Fact000016">Suite 3001</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-03-31" id="Fact000017">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-03-31" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-03-31" id="Fact000019">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-03-31" id="Fact000020">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-03-31" id="Fact000021">266-7344</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-03-31" id="Fact000022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-03-31" id="Fact000023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-03-31" id="Fact000024">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2026-01-01to2026-03-31" id="Fact000025">false</dei:EntityExTransitionPeriod>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000031"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000033"
      unitRef="USD">590</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">590</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000041"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">-590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">590</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">-590</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">-590</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">-590</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000069"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000071"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000073"
      unitRef="USDPShares">-5.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000075"
      unitRef="USDPShares">-5.90</us-gaap:EarningsPerShareDiluted>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFeeShares
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFeeShares>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000086"
      unitRef="USD">100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000088"
      unitRef="USD">-100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">-590</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">-590</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000100"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000101"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000102"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">-590</us-gaap:NetIncomeLoss>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">590</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:StockIssued1
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">100</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="From2025-12-192025-12-31" id="Fact000137">&lt;p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 &#x2014; &lt;span id="xdx_821_zu9lUW4uEBC"&gt;Description of Organization and
Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Business Operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;D. Boral ARC Merger Corporation
(the &#x201c;Company&#x201d; or &#x201c;PubCo&#x201d;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#x201c;Parent&#x201d;
or &#x201c;BCAR&#x201d;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-12-192025-12-31" id="Fact000143">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2014; &lt;span id="xdx_827_z1QOLi23x5K2"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zJc7JPdBlxC3"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zieh9LOsfqE3"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zE9hBnagYMVa"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_863_zT2IwjyYxMwg"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_ziSLvQsMEBHb"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic loss
per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zTUwRw7Nlatj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zM7M5EBTVgG3"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000145">&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zJc7JPdBlxC3"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000147">&lt;p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zieh9LOsfqE3"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-12-192025-12-31" id="Fact000150">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zE9hBnagYMVa"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000152">&lt;p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_863_zT2IwjyYxMwg"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000154">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_ziSLvQsMEBHb"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000156">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic loss
per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-12-192025-12-31" id="Fact000159">&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zTUwRw7Nlatj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000161">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zM7M5EBTVgG3"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000163">&lt;p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zWj9pExp7IJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3&#x2009;&#x2014;&#x2009;&lt;span&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_823_zBCYtPTrZJgj" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 280, &#x201c;Segment
Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s chief operating
decision maker has been identified as directors (&#x201c;CODM&#x201d;), who review the operating results for the Company as a whole to make
decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only
has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The key measures of segment profit
or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by the CODM
to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period.
The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned
with all agreements and budget.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000166">&lt;p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zJxmo93c5NE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span id="xdx_825_zpHDqrU5OLkc"&gt;Business Combination&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#x201c;PubCo&#x201d;),
D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination will be effected in
two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining as the surviving
publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub will be merged with
and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d; and together with
the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate consideration for
the Acquisition Merger is $&lt;span id="xdx_906_ecustom--AggregateConsideration_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pp0p" title="Aggregate consideration"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="New shares issued"&gt;50,000,000&lt;/span&gt; newly issued shares
of common stock of PubCo valued at $&lt;span id="xdx_902_eus-gaap--SharePrice_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="Share Price"&gt;10.00&lt;/span&gt; per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#x201c;Closing&#x201d;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each issued and
        outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the
        Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b) Ten
        Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each issued and
        outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
        by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cik0002065779:AggregateConsideration
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="0"
      id="Fact000168"
      unitRef="USD">500000000</cik0002065779:AggregateConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000174">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhxdEDXzYVGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span id="xdx_826_z8QPFSfZW7Qi"&gt;Share Capital&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company is authorized to issue
&lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z5fNqfWf2Exk" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zUx4YfEZD1lg" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. Holders of the Company&#x2019;s common stock are entitled to one vote for each
share. On December&#160;19, 2025, the Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zATkjkJr6MK4" title="Common stock issued"&gt;100&lt;/span&gt; shares of common stock to its Parent D. Boral ARC Acquisition I Corp., at a purchase
price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_z76UKaf0Ad1g" title="Purchase price"&gt;1.00&lt;/span&gt; per share, or an aggregate purchase price of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zeyJujuSXK4h" title="Aggregate purchase price"&gt;100&lt;/span&gt;. The subscription fee was not received yet as of December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000184"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-12-192025-12-31" id="Fact000186">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zdsxE17ClwOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2014; &lt;span id="xdx_827_zf6PwHW1lV13"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In preparing the financial statements,
the Company considered disclosures of events occurring after December&#160;31, 2025, until the issuance of the financial statements. Based
on this review, the Company identified the following subsequent event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#x201c;PubCo&#x201d;),
D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;).&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <cik0002065779:AmountDueToRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">10000</cik0002065779:AmountDueToRelatedParty>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">590</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">10590</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">590</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">10590</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-10590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">10000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-10000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-10000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-10000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000245"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-100.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000250"
      unitRef="USDPShares">-100.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-10000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-10000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-10000</us-gaap:NetIncomeLoss>
    <cik0002065779:PaymentOfExpensesThroughRelatedParty
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">10000</cik0002065779:PaymentOfExpensesThroughRelatedParty>
    <us-gaap:NatureOfOperations contextRef="From2026-01-01to2026-03-31" id="Fact000300">&lt;p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 &#x2014; &lt;span&gt;&lt;span id="xdx_824_zEQebogyAwxh"&gt;Description of Organization
and Business Operations&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Business Operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;D. Boral ARC Merger Corporation
(the &#x201c;Company&#x201d; or &#x201c;PubCo&#x201d;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#x201c;Parent&#x201d;
or &#x201c;BCAR&#x201d;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000304"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000306">&lt;p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2014; &lt;span&gt;&lt;span id="xdx_82F_z8WT7pqmunKd"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zRelC9ayrXw9"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zu39EgO8Buwg"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zvzbCsC8L8Ff"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86D_zOSz8DGNyjqf"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zOgsMgqR3B78"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_z5LJmpNKovA1"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic
loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zAu283mu3nxe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zIe1QxnsUF6c"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000308">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zRelC9ayrXw9"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000310">&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zu39EgO8Buwg"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-03-31" id="Fact000313">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zvzbCsC8L8Ff"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000315">&lt;p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86D_zOSz8DGNyjqf"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000317">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zOgsMgqR3B78"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000319">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_z5LJmpNKovA1"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic
loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-03-31" id="Fact000322">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zAu283mu3nxe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000324">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zIe1QxnsUF6c"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000326">&lt;p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_ziZWg2OvQdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3&#x2009;&#x2014;&#x2009;&lt;span&gt;&lt;span&gt;Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_82C_z7uy5yMbcEtj" style="display: none"&gt;Segment information&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 280, &#x201c;Segment
Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s chief
operating decision maker has been identified as directors (&#x201c;CODM&#x201d;), who review the operating results for the Company as a
whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the
Company only has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The key measures of segment
profit or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by
the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination
period. The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs
are aligned with all agreements and budget.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000329">&lt;p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zz0pi87aYuh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span&gt;&lt;span id="xdx_82A_zmgpl2ui5l4b"&gt;Business Combination&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026,
D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the
&#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;
and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate consideration
for the Acquisition Merger is $&lt;span id="xdx_900_ecustom--AggregateConsideration_pp0d_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zXXqwXv1BXGd" title="Aggregate consideration"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zocbYDaoU3K4" title="New shares issued"&gt;50,000,000&lt;/span&gt; newly issued shares
of common stock of PubCo valued at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zRXflzuZMDy4" title="Share Price"&gt;10.00&lt;/span&gt; per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#x201c;Closing&#x201d;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each
    issued and outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the
    quotient equal to the Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;)
    by (b) Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each
    issued and outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the
    Per Share Merger Consideration by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cik0002065779:AggregateConsideration
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="0"
      id="Fact000331"
      unitRef="USD">500000000</cik0002065779:AggregateConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000333"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000335"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000337">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z85SDJ4YhdWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span&gt;&lt;span id="xdx_822_zaJ0zlFDAKm2"&gt;Share Capital&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company is authorized
to issue 100 shares of Common Stock of par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zGw25nXRyHs8" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. Holders of the Company&#x2019;s common stock are entitled to one
vote for each share. On December&#160;19, 2025, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zTgHwRfLctwa" title="Common stock issued"&gt;100&lt;/span&gt; shares of common stock to its Parent D. Boral ARC Acquisition
I Corp., at a purchase price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zFcXUa3HlvSa" title="Purchase price"&gt;1.00&lt;/span&gt; per share, or an aggregate purchase price of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zAz0GKFnQxRf" title="Aggregate purchase price"&gt;100&lt;/span&gt;. The subscription fee was not received yet as
of March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000339"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453"
      decimals="INF"
      id="Fact000343"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000347">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zjwom0VPgJzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2014; &lt;span&gt;&lt;span id="xdx_828_z3M5gtjk58V7"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In preparing the financial
statements, the Company considered disclosures of events occurring after March 31, 2026, until the issuance of the financial statements.
Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">203134</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">623474</us-gaap:AssetsCurrent>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">285400102</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000367"
      unitRef="USD">37611</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">37611</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">37611</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000377"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000385"
      unitRef="USDPShares">10.17</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">284776628</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000391"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000399"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000411"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000413"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000415"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">584543</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000427"
      unitRef="USD">285400102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">320658</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-320658</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">4455970</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000439"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000440"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000441"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000443"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000444"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000445"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000465"
      unitRef="Shares">12321429</cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1232</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">23768</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">25000</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCostsShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">200000</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCostsShares>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">20</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">1971400</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">1971420</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">8913405</cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">8913405</cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfRepresentativeSharesShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">1000000</cik0002065779:IssuanceOfRepresentativeSharesShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000483"
      unitRef="USD">100</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">2419300</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">2419400</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000494"
      unitRef="USD">14233074</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">4301388</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000497"
      unitRef="USD">18534462</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">860414</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">429961</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">1290375</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ForfeitureOfFounderSharesShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">-321429</cik0002065779:ForfeitureOfFounderSharesShares>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">32</cik0002065779:ForfeitureOfFounderShares>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">-32</cik0002065779:ForfeitureOfFounderShares>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">44755</cik0002065779:AdjustmentOfAccruedOfferingCosts>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">44755</cik0002065779:AdjustmentOfAccruedOfferingCosts>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">4455970</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">4455970</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000536"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000538"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">584543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">4455970</us-gaap:NetIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">41420</cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">203134</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000554"
      unitRef="USD">37611</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">-444761</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">280000000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-280000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000566"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000568"
      unitRef="USD">280000000</cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000570"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">225461</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">934438</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">280865101</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesIssued1
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">32</us-gaap:NotesIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">4776628</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDescription
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000590">2,419,400</us-gaap:NoncashOrPartNoncashAcquisitionDescription>
    <us-gaap:NatureOfOperations
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000592">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zLLaTa8ZGhCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82D_zfE85CfSiSl"&gt;DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;D.
BORAL ARC ACQUISITION I CORP. (the &#x201c;Company&#x201d;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (&#x201c;Business Combination&#x201d;). While the Company may pursue an acquisition
opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries that complement our
management team&#x2019;s background, and to capitalize on the ability of our management team to identify and acquire a business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December&#160;31, 2025, the Company had not yet commenced any operations. All activity through December&#160;31, 2025 related to the Company&#x2019;s
formation and the Initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s sponsor is MFH 1, LLC (the &#x201c;Sponsor&#x201d;). The registration statement for the Company&#x2019;s Initial Public Offering
was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zymewYmUk4Hc" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt;
units (the &#x201c;Units&#x201d; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#x201c;Public
Shares&#x201d;), at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLpBFIdH2am2" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeMvai1aOgU5" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt; (the &#x201c;Initial Public Offering&#x201d;). The Company
granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zvvgsX2GXdI2" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover
over-allotments, if any.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1oRfYkYwYg7" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; units (the
&#x201c;Placement Units&#x201d;) to the Sponsor at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztuGwqkmsSn4" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6JLWVjCNLD2" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; (the &#x201c;Private
Placement&#x201d;). (see Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction
costs amounted to $&lt;span id="xdx_90D_ecustom--TransactionCosts_pp0p0_c20250320__20251231_zWv4AjHSzFBk" title="Transaction costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_900_ecustom--RepresentativeShares_pp0p0_c20250320__20251231_zfnVet6jBnE8" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (discussed in the below) and $&lt;span id="xdx_900_ecustom--OtherOfferingCosts_pp0p0_c20250320__20251231_zzbsFZ9QoI29" title="Other offering costs"&gt;1,163,234&lt;/span&gt; of other offering
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the IPO, the Company issued to the underwriter &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z9JyvNUCifek" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Class A ordinary shares for no consideration (the &#x201c;Representative
Shares&#x201d;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#x201c;ASC&#x201d;)
718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;) is included in the offering costs. The estimated fair
value of the Representative Shares as of the IPO date totaled $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zkjrdeMbCkic" title="Number of share issued, value"&gt;2,419,400&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zAYQK4eRIMDe" title="proceeds from sale of initial public offering"&gt;250,000,000&lt;/span&gt; ($10.00 per Unit) from the net proceeds of
the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in
a trust account (the &#x201c;Trust Account&#x201d;), located in the United States and held as cash items and will be invested only in U.S.
government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under
the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form
is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the
Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the
Company hold investments in the trust account, the Company may, at any time (based on our management team&#x2019;s ongoing assessment of
all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held
in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a
bank.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased
&lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zDA2VnME7U0b" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR9U3nh9D7Y8" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating
gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlDHmMAY5wM4" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. The over-allotment option closed on August&#160;13, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and
thereby forfeit the option. As a result,&#160;on September&#160;9, 2025,&#160;the Company cancelled a total of &lt;span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zuJm4Jjl1XIk" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; of the Company&#x2019;s
founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#x2019;s total shares to &lt;span id="xdx_909_ecustom--CancelledFounderShares_c20250729__20250801_z24hspa4c7wl" title="Cancelled founder shares"&gt;12,000,000&lt;/span&gt;, which was effective from August&#160;1,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion
of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a
Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they
vote for the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially
$&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi26VOwh3vcj" title="Sale of units per share"&gt;10.00&lt;/span&gt; per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company
to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced
by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value
and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification
(&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company
will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4
and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing
our initial business combination which contain substantially the same financial and other information about the initial business combination
and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive
their redemption rights with respect to their founder shares, private shares and public shares in connection with the completion of our
initial business combination; (ii) waive their redemption rights with respect to their founder shares, private shares and public shares
in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the
Company fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial business
combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and (iv) vote any
founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated
transactions) in favor of our initial business combination (except that any public shares such parties may purchase in compliance with
the requirements of Rule&#160;14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of
the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend
the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of
directors may approve, to consummate a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete
a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor),
redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $&lt;span id="xdx_900_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zMMxKKn8j5Nc" title="Dissolution expenses"&gt;100,000&lt;/span&gt; of interest to pay
dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#x2019;
rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors,
liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and
the requirements of other applicable law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company
does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds
held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is
possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price
per Unit ($10.00).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold
to us (except for the Company&#x2019;s independent auditors), or a prospective target business with which the Company has entered into
a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in
the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account
as of the date of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust
assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business
who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will
it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the
Securities Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#x2019;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and
Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition
Merger&#x201d; and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate consideration for the Acquisition Merger is $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250320__20251231_zLQu92JYDcL4" title="Share newly issued of common stock"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231_zrpwY2DyvnT9" title="Share newly issued of common stock, shares"&gt;50,000,000&lt;/span&gt;
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#x201c;Closing&#x201d;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each issued and outstanding share
        of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class B common
        stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the Merger Consideration
        divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b) Ten Dollars ($10.00), with
        each such PubCo Class B Share having twenty (20) votes per share; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each issued and outstanding share
        of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class A common
        stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration by (b)
        Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity,
Capital Resources and Going Concern Consideration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2025, the Company had $&lt;span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20251231_zBQBHTAL4Sk4" title="Cash"&gt;420,340&lt;/span&gt; of cash in its operating bank account and working capital of $&lt;span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20251231_zaoDT1sVQ0Cb" title="Working capital deficit"&gt;585,863&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zd9iA0x85lrl"&gt;25,000&lt;/span&gt;
from the Sponsor to cover for certain offering costs on the Company&#x2019;s behalf in exchange for issuance of Founder Shares (as defined
in Note 4), and loan from the Sponsor of $&lt;span id="xdx_900_eus-gaap--LoansPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z97qhlWYqK2h"&gt;225,461&lt;/span&gt; under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid
$&lt;span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zb9jcZE28Ibk"&gt;225,461&lt;/span&gt; under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate
of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, provide the Company Working Capital
Loans (as defined in Note 4). As of December&#160;31, 2025, there were no amounts outstanding under any Working Capital Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after
the completion of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it
pursues an initial business combination target. In connection with the Company&#x2019;s assessment of going concern considerations in accordance
with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue
as a Going Concern&#x201d; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing
a Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors,
or third parties. The Company&#x2019;s officers and directors and the Sponsor may, but are not obligated to (except as described above),
loan the Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s
working capital needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
is customary for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination
Period, it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company expects to have access to additional sources of capital if necessary, there is no current commitment on the part of any financing
source to provide additional capital and no assurances can be provided that such additional capital will ultimately be available. The
liquidity condition and mandatory liquidation raise substantial doubt about the Company&#x2019;s ability to continue as a going concern
until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance
that the Company&#x2019;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination
will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000596"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000604"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000606"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:TransactionCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">3582634</cik0002065779:TransactionCosts>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">2419400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000618"
      unitRef="USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000629"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">12000000</cik0002065779:CancelledFounderShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">500000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">420340</us-gaap:Cash>
    <cik0002065779:WorkingCapitalDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">585863</cik0002065779:WorkingCapitalDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">225461</us-gaap:LoansPayable>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000664"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000673">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zy7FcDCgeNii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_82E_z6Po6lfWFJF7"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zknhPtMT4xkj"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z9adgwwH5gz6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z9wBQjRDfAXk"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zAhdNNso56Nb"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $&lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash"&gt;420,340&lt;/span&gt; in cash as of December&#160;31, 2025 The Company
had &lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zTYNKhDkXdT7"&gt;Cash
Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust"&gt;284,776,628&lt;/span&gt; of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zHG5bezvliwj"&gt;Offering
Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#x2019;s
equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $&lt;span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs"&gt;143,775&lt;/span&gt; of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt; was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zcqL0aCgOVV7"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be &lt;i&gt;de minimis&lt;/i&gt; for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zun6kxhx1xka"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDBCwQoAzPGl"&gt;Warrant
Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#x2019;s common shares and whether the instrument holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of a company&#x2019;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued"&gt;14,000,000&lt;/span&gt; public warrants and&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their
assigned values. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMsjsksIRMVh"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zQunJD1xUwzi"&gt;Net
Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zU8Q18WJlnoi"&gt;Concentration
of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbcnfxYlFdrl"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zjcWV21IYFn1"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zJUe6H2lTeAa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial
position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000675">&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zknhPtMT4xkj"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000677">&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z9adgwwH5gz6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000686">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z9wBQjRDfAXk"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000688">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zAhdNNso56Nb"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $&lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash"&gt;420,340&lt;/span&gt; in cash as of December&#160;31, 2025 The Company
had &lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CashHeldInTrustAccountPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000694">&lt;p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zTYNKhDkXdT7"&gt;Cash
Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust"&gt;284,776,628&lt;/span&gt; of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:CashHeldInTrustAccountPolicyTextBlock>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000698">&lt;p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zHG5bezvliwj"&gt;Offering
Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#x2019;s
equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $&lt;span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs"&gt;143,775&lt;/span&gt; of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt; was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCost
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCost>
    <us-gaap:OtherExpenses
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">143775</us-gaap:OtherExpenses>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">3438859</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000719">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zcqL0aCgOVV7"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be &lt;i&gt;de minimis&lt;/i&gt; for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000721">&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zun6kxhx1xka"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:ExtendedProductWarrantyPolicy
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000723">&lt;p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDBCwQoAzPGl"&gt;Warrant
Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#x2019;s common shares and whether the instrument holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of a company&#x2019;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued"&gt;14,000,000&lt;/span&gt; public warrants and&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their
assigned values. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">14000000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightUnissued>
    <cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000736">&lt;p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMsjsksIRMVh"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000738">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">280000000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <cik0002065779:ProceedsAllocatedToPublicWarrants
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">-9028600</cik0002065779:ProceedsAllocatedToPublicWarrants>
    <cik0002065779:ProceedsAllocatedToOverallotmentOption
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">-1290375</cik0002065779:ProceedsAllocatedToOverallotmentOption>
    <cik0002065779:ClassOrdinarySharesIssuanceCosts
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000746"
      unitRef="USD">-3438859</cik0002065779:ClassOrdinarySharesIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">18534462</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000750"
      unitRef="USD">284776628</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000752">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zQunJD1xUwzi"&gt;Net
Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">14100000</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000763">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000765"
      unitRef="USD">2509890</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">2509890</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="0"
      id="Fact000768"
      unitRef="USD">1946080</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">1946080</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000780"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000782"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000784"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000788">&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zU8Q18WJlnoi"&gt;Concentration
of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000792">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbcnfxYlFdrl"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000794">&lt;p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zjcWV21IYFn1"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000803">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zJUe6H2lTeAa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial
position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cik0002065779:InitialPublicOfferingDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000805">&lt;p id="xdx_80D_ecustom--InitialPublicOfferingDisclosureTextBlock_zSLJnITYDvT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_82B_z1KbCnrudoXf"&gt;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z68SWSkXouvl" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; Units, at $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuYTl7DjGW56" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds
of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNsLNzuqxtP2" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt;. The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zLyPTOsY05De" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public
Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial
exercise of the over-allotment option and purchased &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2DvOPHYNdv4" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5FkLaLYZBbb" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon
the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zF2cRkgObqV" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September&#160;9, 2025, the Underwriters advised
the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists
of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary
share at a price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vX2ACUCNo7" title="Share price"&gt;11.50&lt;/span&gt; per share, subject to adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000809"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000817"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">11.50</us-gaap:SharePrice>
    <cik0002065779:PrivatePlacementDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000823">&lt;p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zpb49dy82Zdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_82F_zsyzzDUiuM6e"&gt;PRIVATE PLACEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zock4izgOfti" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; Private Units at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwMvmX5ifFuc" title="Sale of units per share"&gt;10.00&lt;/span&gt; per
Placement Unit raising $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIzdEwofmxtc" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement
Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business
Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the
Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













</cik0002065779:PrivatePlacementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000827"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000836">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrYpFvvjFz9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_825_zCNNFCMF78fe"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Founder
Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March&#160;25, 2025, the Company issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zKIH67EkvYIj" title="Shares issued"&gt;12,321,429&lt;/span&gt; founder shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zGVXdJ6E6tx1" title="Cash"&gt;25,000&lt;/span&gt;
in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August&#160;11,
2025, on September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment
option and thereby forfeit the option. As a result, on September&#160;9, 2025, the Company cancelled a total of &lt;span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zl4zcqqhZ3uf" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; founder shares.
As of December&#160;31, 2025, sponsor held a total of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zrz4M0un8z1i" title="Forfeiture shares"&gt;12,000,000&lt;/span&gt; founder shares and none was subject to forfeiture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
founder shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A ordinary shares
included in the units being sold in the IPO, and holders of founder shares have the same shareholder rights as public shareholders, except
that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are
entitled to registration rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection
with the completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles
of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem &lt;span id="xdx_908_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20250320__20251231_zW3TNlBemkUl" title="Percentage of redemption of public shares"&gt;100%&lt;/span&gt; of our public shares if we have not consummated an initial business combination within the completion window or (b)
with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial business combination activity, (C)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail
to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within such
time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them and any
public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination
(except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act
would not be voted in favor of approving the business combination transaction), (iv) the founder shares are automatically convertible
into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination or earlier
at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in our amended and restated memorandum
and articles of association, and (v) prior to the closing of our initial business combination, only holders of our Class B ordinary shares
will be entitled to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside the British Virgin
Islands (including any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in
each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and
other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion
of our initial business combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Promissory
Note &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March&#160;20, 2025, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an
aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251231__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember_zilx2XNUQ3Jd" title="Principal amount"&gt;350,000&lt;/span&gt;, to be used for payment of costs related to the Proposed Offering. The note is non-interest bearing
and payable on the earlier of (i) December&#160;31, 2025 or (ii) the consummation of the Initial Public Offering. On August&#160;1, 2025,
the Company has repaid $&lt;span id="xdx_901_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zNBRf0ZD3Bcg" title="Repayment of promissory note"&gt;225,461&lt;/span&gt; under the promissory note with the Sponsor out of the $&lt;span id="xdx_90B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcDb7GEDXP32" title="Payment of offering expenses"&gt;700,000&lt;/span&gt; of offering proceeds that has been allocated
for the payment of offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Administrative
Services Arrangement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
affiliate of our Sponsor has agreed, commencing from the date that the Company&#x2019;s securities are first listed on Nasdaq, through
the earlier of the Company&#x2019;s consummation of a Business Combination and its liquidation, to make available to the Company our Sponsor
certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. The Company has
agreed to pay to the affiliate of our Sponsor, $&lt;span id="xdx_900_eus-gaap--PaymentsOfDistributionsToAffiliates_c20250320__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zlnaPZbdyeKh" title="Payment to affiliate"&gt;20,000&lt;/span&gt; per month, for up to 18 months, subject to extension to up to 21 months, for such
administrative services. For the period from March&#160;20, 2025 (inception) to December&#160;31, 2025, $&lt;span id="xdx_909_eus-gaap--AdministrativeFeesExpense_c20250320__20251231_zx13woO4Tfnc" title="Administrative services"&gt;100,000&lt;/span&gt; was charged to operations
and no amounts were outstanding at December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Related
Party Loans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to finance transaction costs in connection with a Business Combination, the Company&#x2019;s Sponsor or an affiliate of the Sponsor,
or the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working
Capital Loans&#x201d;). Up to $&lt;span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoSGVPE4L9ll" title="Conversion of debt"&gt;2,500,000&lt;/span&gt; of such loans may be convertible into private units, at a price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoryQ0v2dVwg" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit, at the option
of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside
the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. As of December&#160;31, 2025, no amounts under such loans have been drawn.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Representative
Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;1, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zEnpb1MH6gf7" title="Number of share issued"&gt;1,000,000&lt;/span&gt; representative shares to D. Boral Capital, LLC and/or its designees (whether or not
the over-allotment is exercised) as part of representative compensation (the &#x201c;Representative Shares&#x201d;). The Representative
Shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the
commencement of sales of the IPO pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold,
transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would
result in the economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial
Public Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in
the Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale registration
rights including two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and unlimited &#x201c;piggy-back&#x201d;
rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">25000</us-gaap:Cash>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">12000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Ratio">1</cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">350000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">700000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">20000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">100000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">2500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000871">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOodEbadoGl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_827_zvnDuwuTDke4"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Registration
Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii)
Private Units (including the component securities as well as any securities underlying those component securities), which was issued in
a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities
as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have
registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company
acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to
or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding
short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration
rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights
granted to the underwriter are limited to two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense)
and unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underwriting
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has granted the underwriters a 45-day option to purchase up to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFjNTzXClord" title="Option granted"&gt;3,750,000&lt;/span&gt; additional Units to cover over-allotments at the Initial
Public Offering price, less the underwriting discounts and commissions. On August&#160;11, 2025, the underwriters of the IPO notified
the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsDsQ7BIzSY4" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;)
at $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z00hlruxNby8" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zTKQ26a264L8" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September&#160;9, 2025,
the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled
to &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z7WKxjLfpBE3" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters
will not be entitled to any deferred underwriting fee upon closing of the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000884"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000890">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLymJvSLjwni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_829_zo6eGMSSg8H3"&gt;STOCKHOLDER&#x2019;S EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preference
shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20251231_zVKs3Ud7A2J1" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; preference shares with a par value of $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zGdq3Sz7TMP2" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. Holders of the
Company&#x2019;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025, there were &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zes6MDUpNOee" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zggQcNldTD8j" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; preferred shares issued
or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
A Ordinary shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zUIiqFEC1YKa" title="Common stock, shares authorized"&gt;500,000,000&lt;/span&gt; ordinary shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zpG2arjDcUM5" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share. Holders
of the Company&#x2019;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and the partial exercise
of the over-allotment option partial exercise of the over-allotment option, there were &lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zX4U9Oph6c9b" title="Common stock, shares outstanding"&gt;1,200,000&lt;/span&gt; Class A ordinary shares issued or outstanding,
excluding &lt;span id="xdx_90D_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zM1hbLvnyh4d" title="Ordinary shares subject to possible redemption"&gt;28,000,000&lt;/span&gt; Class A ordinary shares subject to possible redemption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
B Ordinary shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaDu9F4i7evd"&gt;50,000,000&lt;/span&gt; ordinary shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaOL9jf9dkb3"&gt;0.0001&lt;/span&gt; per share. Holders
of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company issued an aggregate
of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zfTMSHKHds0l"&gt;12,321,429&lt;/span&gt; ordinary shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90D_ecustom--AggregatePurchasePrice_iI_pp0p0_c20250325_ztIeXeeDmxNc" title="Aggregate purchase price"&gt;25,000&lt;/span&gt; in cash, of which &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zxJWaCgaTD7h"&gt;1,607,143&lt;/span&gt; shares held by the
Sponsor are subject to forfeiture to the extent that the underwriter&#x2019;s over-allotment option is not exercised in full. Following
the partial exercise of the over-allotment option on August&#160;11, 2025 and cancellation &lt;span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zQ94bGRQlFb7" title="Cancellation of ordinary shares"&gt;321,429&lt;/span&gt; ordinary shares on September&#160;9,
2025, on December&#160;31, 2025, there were &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zigcy70u45ba" title="Common stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zX4NnnaGuwf" title="Common stock, shares outstanding"&gt;12,000,000&lt;/span&gt;&lt;/span&gt; ordinary shares issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation
of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject
to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders
will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in
the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed
issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the
Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and
outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance)
so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 30%
of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary
shares issued pursuant to the underwriters&#x2019; over-allotment option and excluding the Class A ordinary shares that are included within
the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the
closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in
the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion
of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial
business combination; provided that such conversion of founder shares will never occur on a less than &lt;span id="xdx_904_eus-gaap--CommonStockConversionBasis_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zwHvTm6YpHfl" title="Conversion basis"&gt;one-for-one basis&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of record of the Company&#x2019;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all
matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required
by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum
and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being
entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally
required to approve any matter voted on by the Company&#x2019;s shareholders. Approval of certain actions require an ordinary resolution
under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes
cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general
meeting, and pursuant to the Company&#x2019;s amended and restated memorandum and articles of association, such actions include amending
the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company.
There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#x2019;s initial Business Combination,
the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the
consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment
and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including
any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result
of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary
shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles
of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at
least 90% of the issued Class B ordinary shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
&#x2014; &lt;/i&gt;Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants.
The Warrants will become exercisable &lt;span id="xdx_900_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20250320__20251231_zqmaOpl3oGMf" title="Period of warrants exercisable"&gt;30&lt;/span&gt; days after the completion of our initial business combination, provided that the Company has an
effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants
and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the
securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis
under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable
upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain
an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the
Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1)
of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#x201c;cashless
basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file
or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or
earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may call the Warrants for redemption:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
        whole and not in part;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at
        a price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z0R8vEvtgNEk" title="Warrant price"&gt;0.01&lt;/span&gt; per warrant; upon a minimum of &lt;span id="xdx_908_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20250320__20251231_zrGTHCbEFza3" title="Holders of warrants"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption (the &#x201c;30-day redemption period&#x201d;);
        and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if,
        and only if, the closing price of the Class A ordinary shares equals or exceeds $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zm2Uo06WbIbb" title="Share price"&gt;18.00&lt;/span&gt; per share (as adjusted for adjustments to the number
        of shares issuable upon exercise or the exercise price of a warrant) for any &lt;span id="xdx_904_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_z9LF9cWDtqp1" title="Number of trading days"&gt;20&lt;/span&gt; trading days within a &lt;span id="xdx_901_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zO5hmy55kbj4" title="Number of consecutive trading days"&gt;30&lt;/span&gt;-trading day period commencing
        at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption
        to the warrant holders.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees,
the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration
rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations,
reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants.
If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in
the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution
from the Company&#x2019;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire
worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at
an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial
business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the
&lt;span id="xdx_90F_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zwi57d75Gbnf" title="Number of trading days"&gt;20&lt;/span&gt; trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price,
the &#x201c;Market Value&#x201d;) is below $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231_z9oNRy7TT9cb" title="Warrants exercise price"&gt;9.20&lt;/span&gt; per share, then the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to &lt;span id="xdx_90C_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20251231_zqUGRVZptye" title="Market value"&gt;115%&lt;/span&gt; of the higher of the Market Value and the Newly Issued Price, and the $&lt;span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20251231_zMU6AAn42sQf" title="Redemption price"&gt;18.00&lt;/span&gt; per share redemption trigger prices will
be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20251231_zSYWzSorZM4l" title="Share redemption trigger prices"&gt;180%&lt;/span&gt; of the higher of the Market Value and the Newly Issued Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000907"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cik0002065779:AggregatePurchasePrice
      contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">25000</cik0002065779:AggregatePurchasePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">1607143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cik0002065779:CancellationOfOrdinaryShares
      contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">321429</cik0002065779:CancellationOfOrdinaryShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000920">one-for-one basis</us-gaap:CommonStockConversionBasis>
    <cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000929">P30D</cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000933">P30D</cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000935"
      unitRef="USDPShares">18.00</us-gaap:SharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000937">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000939">P30D</cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000948">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000950"
      unitRef="USDPShares">9.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Ratio">1.15</us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000954"
      unitRef="USDPShares">18.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <cik0002065779:ShareRedemptionTriggerPrices
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000956"
      unitRef="Ratio">1.80</cik0002065779:ShareRedemptionTriggerPrices>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000958">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zhQ9pqoDD5x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_821_zmhkA80TXS8d"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets that are measured at fair value as of August&#160;1, 2025 and
December&#160;31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair
value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B6_zXfmlkhV9ysd" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Liability:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Fair value of over-allotment liability&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability"&gt;1,290,375&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Equity:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity"&gt;8,061,250&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zKnLC9z1gto9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
over-allotment option was accounted for as a liability in accordance with ASC 815-40 and was presented within liabilities on the balance
sheet. The over-allotment option liability is measured at fair value at August&#160;1, 2025 and on a recurring basis, with changes in
fair value presented within change in fair value of over-allotment option liability in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level
3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models and assumptions
related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary
share based on historical volatility that matches the expected remaining life of the over-allotment option. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the over-allotment
option. The expected life of the over-allotment option is assumed to be equivalent to its remaining contractual term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B7_zoaVPMUgkntk" style="display: none"&gt;Schedule of initial measurement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate"&gt;4.31&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility"&gt;22.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Fair value of over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option"&gt;0.3441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zhBNM0cZxCt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of Public Warrants was determined using Monte Carlo Simulation Model. The Public Warrants have been classified within shareholders&#x2019;
equity and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions
used in the valuation of the Public Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BE_zsvTOTvZXEk3" style="display: none"&gt;Schedule of market assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Estimated share price&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Annual risk-free rate (term-matched)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected warrant implied volatility based
        on warrants from comparable SPAC securities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities"&gt;14.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zvYcYlSuTAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000967">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B6_zXfmlkhV9ysd" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Liability:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Fair value of over-allotment liability&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability"&gt;1,290,375&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Equity:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity"&gt;8,061,250&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">1290375</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure
      contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">8061250</us-gaap:EquityFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000973"
      unitRef="USD">284776628</us-gaap:AssetsFairValueDisclosure>
    <cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000975">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B7_zoaVPMUgkntk" style="display: none"&gt;Schedule of initial measurement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate"&gt;4.31&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility"&gt;22.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Fair value of over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option"&gt;0.3441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Ratio">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000979">P0Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Ratio">0.227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000983"
      unitRef="USDPShares">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <cik0002065779:FairValueOfOverallotmentOption
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">0.3441</cik0002065779:FairValueOfOverallotmentOption>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000987">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BE_zsvTOTvZXEk3" style="display: none"&gt;Schedule of market assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Estimated share price&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Annual risk-free rate (term-matched)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected warrant implied volatility based
        on warrants from comparable SPAC securities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities"&gt;14.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000993">P2Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Ratio">0.0375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Ratio">0.1444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001003">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zlDYq8wDTeqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_82A_ziXv0oR4ze67" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statement information about
operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise
for which separate financial information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker,
or group, in deciding how to allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision maker has been identified as the Chief Financial Officer (&#x201c;CODM&#x201d;), who reviews the
operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly,
management has determined that the Company only has one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics,
which include the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_8BC_zWWW3w6SRnKb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(inception) through&lt;br/&gt;December&#160;31,&lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Formation
        and operating costs&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs"&gt;(320,658&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on
        cash held in trust account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account"&gt;4,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust
        Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key measures of segment profit or loss reviewed by the CODM are formation and operating costs, interest income on cash held in trust account,
and cash held in trust account. The CODM reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder
value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust
agreement. Within the operating expenses, the CODM specifically reviews professional service fees, which are a significant segment expense,
and include legal fees and advisory fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination
within the required period. Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory
filing fees, are reviewed in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account
represent the predominant portion of the Company&#x2019;s total assets and are monitored by the CODM to determine the most effective strategy
of investment with the Trust Account funds, while maintaining compliance with the trust agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001005">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_8BC_zWWW3w6SRnKb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(inception) through&lt;br/&gt;December&#160;31,&lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Formation
        and operating costs&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs"&gt;(320,658&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on
        cash held in trust account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account"&gt;4,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust
        Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">320658</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <cik0002065779:CashHeldInTrustAccounts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccounts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001013">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zAojbVU1a7zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_826_zmvFa0ix0mr6" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC Topic 855, &#x201c;Subsequent Events&#x201d;, which establishes general standards of accounting for and disclosure of
events that occur after the balance sheet date but before consolidated financial statements are issued, the Company has evaluated all
events or transactions that occurred up to the date the consolidated financial statements were available to issue. Based upon this review,
the Company identified the following subsequent events:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and
Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition
Merger&#x201d; and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">243576</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">203134</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001025"
      unitRef="USD">156259</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001027"
      unitRef="USD">623474</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">399835</us-gaap:AssetsCurrent>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001031"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccount>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001033"
      unitRef="USD">285400102</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001034"
      unitRef="USD">287719522</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001042"
      unitRef="USD">37611</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">345713</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">37611</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">345713</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">37611</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001049"
      unitRef="USD">345713</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001057"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001064"
      unitRef="USDPShares">10.26</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">10.17</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">284776628</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001055"
      unitRef="USD">287319687</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001073"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001075"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001081"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001089"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001091"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001103"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001109"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001111"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001113"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001115"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001118"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">584543</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001125"
      unitRef="USD">52802</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">54122</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">285400102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001131"
      unitRef="USD">287719522</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001133"
      unitRef="USD">5420</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">531741</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001140"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">2543059</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001145"
      unitRef="USD">5420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">2011318</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001156"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001160"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001172"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001174"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001178"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact001180"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">584543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001194"
      unitRef="USD">-2543059</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001196"
      unitRef="USD">-2543059</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001201"
      unitRef="USD">2011318</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001203"
      unitRef="USD">2011318</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact001205"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001208"
      unitRef="USD">52802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">54122</us-gaap:StockholdersEquity>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">12321429</cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      decimals="0"
      id="Fact001228"
      unitRef="USD">1232</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">23768</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001231"
      unitRef="USD">-25000</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001239"
      unitRef="USD">-5420</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001241"
      unitRef="USD">-5420</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">12321429</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001244"
      unitRef="USD">1232</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001245"
      unitRef="USD">23768</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">-5420</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001247"
      unitRef="USD">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">-5420</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">5420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">2011318</us-gaap:NetIncomeLoss>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001264"
      unitRef="USD">5420</cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001268"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001274"
      unitRef="USD">-46875</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">308102</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">-176764</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001310"
      unitRef="USD">-176764</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001316"
      unitRef="USD">243576</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">48420</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001325"
      unitRef="USD">2543059</us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001327">&lt;p id="xdx_80C_eus-gaap--NatureOfOperations_zygend9e1RRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 1. &lt;span id="xdx_82D_zrYalJ697s07"&gt;DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;D. BORAL ARC
ACQUISITION I CORP. (the &#x201c;Company&#x201d;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses (&#x201c;Business Combination&#x201d;). While the Company may
pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries
that complement our management team&#x2019;s background, and to capitalize on the ability of our management team to identify and acquire
a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31,
2026, the Company had not yet commenced any operations. All activity through March 31, 2026 related to the Company&#x2019;s formation
and the Initial Public Offering (as defined below). Since the IPO, the Company&#x2019;s activity has been limited to the costs in pursuit
of the consummation of an initial business combination. The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s sponsor is MFH 1, LLC (the &#x201c;Sponsor&#x201d;). The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZC60ip9O139" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; units (the &#x201c;Units&#x201d; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#x201c;Public Shares&#x201d;), at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3ISudk5ZSw6" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjX8VKK92qjd" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt; (the &#x201c;Initial Public Offering&#x201d;). The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z9eUpL924fa5" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover over-allotments, if any. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGrtbDdoicDg" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; units (the &#x201c;Placement Units&#x201d;) to the Sponsor at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zABeT3cNd0K6" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zm3i9GAh1wZ" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; (the &#x201c;Private Placement&#x201d;). (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Transaction costs amounted to $&lt;span id="xdx_90C_ecustom--TransactionCosts_pp0p0_c20260101__20260331_zlNHw2cetME1" title="Transaction costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_905_ecustom--RepresentativeShares_pp0p0_c20260101__20260331_zpYwsp2Au2o7" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (discussed in the below) and $&lt;span id="xdx_90B_ecustom--OtherOfferingCosts_pp0p0_c20260101__20260331_z1IYHYmkc8Vf" title="Other offering costs"&gt;1,163,234&lt;/span&gt; of other offering costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In conjunction with the IPO, the Company issued to the underwriter &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zC8C67MdLPre" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Class A ordinary shares for no consideration (the &#x201c;Representative Shares&#x201d;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;) is included in the offering costs. The estimated fair value of the Representative Shares as of the IPO date totaled $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zHyEfQAcbCTg" title="Number of share issued, value"&gt;2,419,400&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Following the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_ziUw4vAAKbAd" title="proceeds from sale of initial public offering"&gt;250,000,000&lt;/span&gt; ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in a trust account (the &#x201c;Trust Account&#x201d;), located in the United States and held as cash items and will be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the Company hold investments in the trust account, the Company may, at any time (based on our management team&#x2019;s ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJQr08Hr1169" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGc1BiSVx6Wi" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zwO1mOZUQPp7" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. The over-allotment option closed on August&#160;13, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. As a result,&#160;on September 9, 2025,&#160;the Company cancelled a total of &lt;span id="xdx_90C_ecustom--CancelledFounderShares_c20250905__20250909_zMn2lTaGsGg9" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; of the Company&#x2019;s founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#x2019;s total shares to &lt;span id="xdx_90F_ecustom--CancelledFounderShares_c20250729__20250801_zE8aHeKIinuh" title="Cancelled founder shares"&gt;12,000,000&lt;/span&gt;, which was effective from August 1, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they vote for the Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvYo0cYwbk22" title="Sale of units per share"&gt;10.00&lt;/span&gt; per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The sponsor, officers and directors have entered
into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to
their founder shares, private shares and public shares in connection with the completion of our initial business combination; (ii)
waive their redemption rights with respect to their founder shares, private shares and public shares in connection with a
shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the Company
fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial
business combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and
(iv) vote any founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination (except that
any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act would not
be voted in favor of approving the business combination transaction).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of directors may approve, to consummate a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor), redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $&lt;span id="xdx_901_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zW7hO2wBkNSk" title="Dissolution expenses"&gt;100,000&lt;/span&gt; of interest to pay dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#x2019; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The underwriter
has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete
a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust
Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the
per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Sponsor has
agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except
for the Company&#x2019;s independent auditors), or a prospective target business with which the Company has entered into a written letter
of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account
to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date
of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust assets, less
taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed
a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply
to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities
Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#x2019;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January&#160;11,
2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger
(the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;
and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate
consideration for the Acquisition Merger is $500,000,000 (the &#x201c;Merger Consideration&#x201d;), payable in the form of 50,000,000
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#x201c;Closing&#x201d;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt;"&gt;Each issued and outstanding
    share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the
    Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b)
    Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt;"&gt;Each issued and outstanding
    share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
    by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Liquidity, Capital Resources and Going Concern
Consideration&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;As of March 31, 2026, the Company had $&lt;span id="xdx_90D_eus-gaap--Cash_iI_pp0p0_c20260331_zcgybPa75Rrh" title="Cash"&gt;243,576&lt;/span&gt; of cash in its operating bank account and working capital of $&lt;span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_z6EhFQhvkWk2" title="Working capital deficit"&gt;54,122&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s liquidity needs prior to the
consummation of the Initial Public Offering were satisfied through the payment of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zDESmG0pruoc" title="Proceeds from issuance of common stock"&gt;25,000&lt;/span&gt;
from the Sponsor to cover for certain offering costs on the Company&#x2019;s behalf in exchange for issuance of Founder Shares (as
defined in Note 4), and loan from the Sponsor of $&lt;span id="xdx_90F_eus-gaap--LoansPayable_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcxmPKgrvA99" title="Loan payable"&gt;225,461&lt;/span&gt;
under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid $&lt;span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zL71zekeZW5i" title="Repayment of promissory note"&gt;225,461&lt;/span&gt;
under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of
the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an
affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, provide the
Company Working Capital Loans (as defined in Note 4). As of December&#160;31, 2025 and March&#160;31, 2026, there were no amounts
outstanding under any Working Capital Loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects
to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after the completion
of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it pursues an initial
business combination target. In connection with the Company&#x2019;s assessment of going concern considerations in accordance with Accounting
Standards Update (&#x201c;ASU&#x201d;) 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going
Concern&#x201d; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing a Business
Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may
raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors, or third
parties. The Company&#x2019;s officers and directors and the Sponsor may, but are not obligated to (except as described above), loan the
Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s working
capital needs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As is customary
for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination Period,
it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;While the Company expects to have access to
additional sources of capital if necessary, there is no current commitment on the part of any financing source to provide additional
capital and no assurances can be provided that such additional capital will ultimately be available. The liquidity condition and
mandatory liquidation raise substantial doubt about the Company&#x2019;s ability to continue as a going concern until the earlier of
the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance that the
Company&#x2019;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination will
be successful or successful within the Combination Period. The consolidated condensed financial statements do not include any
adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;




















</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:TransactionCosts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">3582634</cik0002065779:TransactionCosts>
    <cik0002065779:RepresentativeShares
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCosts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">2419400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001364"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">12000000</cik0002065779:CancelledFounderShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001372"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">243576</us-gaap:Cash>
    <cik0002065779:WorkingCapitalDeficit
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">54122</cik0002065779:WorkingCapitalDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">225461</us-gaap:LoansPayable>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001403">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwMIFdJLnGU" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 2. &lt;span id="xdx_820_zHeBz4zKHT1d"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Rf2RuPJR21"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and pursuant to the rules and regulations of the SEC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#x2019;s Annual Report on Form 10-K for the year ended
December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zt6czdzfWEih"&gt;Emerging Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zRzz8424e6p3"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zu37CGZfznfc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $&lt;span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5"&gt;420,340&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5"&gt;243,576&lt;/span&gt;
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zgMHfmHrvZ42"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company had $&lt;span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4"&gt;284,776,628&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd"&gt;287,319,687&lt;/span&gt;
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zF0eseXwdsYe"&gt;Offering Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and
Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#x2019;s equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $&lt;span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs"&gt;3,582,634&lt;/span&gt;,
consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares"&gt;2,419,400&lt;/span&gt;
of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs"&gt;143,775&lt;/span&gt;
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt;
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVc6ABTVy162"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be &lt;i&gt;de
minimis&lt;/i&gt; for the three months ended March 31, 2026.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















&lt;p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zpXKgEMQKf8"&gt;Warrant Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#x2019;s common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of a company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued"&gt;14,000,000&lt;/span&gt;
public warrants and&#160;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNHDcMFMuEE"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zHGfCbGDFHJ"&gt;Concentration of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zDDHritlLFyi"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;














&lt;p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_869_zOCJzQXdOYs6"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zJiXM6UsbELc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001405">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Rf2RuPJR21"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and pursuant to the rules and regulations of the SEC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#x2019;s Annual Report on Form 10-K for the year ended
December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001407">&lt;p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zt6czdzfWEih"&gt;Emerging Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001409">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zRzz8424e6p3"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001417">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zu37CGZfznfc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $&lt;span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5"&gt;420,340&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5"&gt;243,576&lt;/span&gt;
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001418"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">243576</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CashHeldInTrustAccountPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001425">&lt;p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zgMHfmHrvZ42"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company had $&lt;span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4"&gt;284,776,628&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd"&gt;287,319,687&lt;/span&gt;
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CashHeldInTrustAccountPolicyTextBlock>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001426"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001427"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001429">&lt;p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zF0eseXwdsYe"&gt;Offering Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and
Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#x2019;s equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $&lt;span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs"&gt;3,582,634&lt;/span&gt;,
consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares"&gt;2,419,400&lt;/span&gt;
of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs"&gt;143,775&lt;/span&gt;
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt;
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001431"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCost
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCost>
    <us-gaap:OtherExpenses
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">143775</us-gaap:OtherExpenses>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">3438859</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001443">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVc6ABTVy162"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be &lt;i&gt;de
minimis&lt;/i&gt; for the three months ended March 31, 2026.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ExtendedProductWarrantyPolicy
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001451">&lt;p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zpXKgEMQKf8"&gt;Warrant Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#x2019;s common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of a company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued"&gt;14,000,000&lt;/span&gt;
public warrants and&#160;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001453"
      unitRef="Shares">14000000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightUnissued>
    <cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001457">&lt;p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNHDcMFMuEE"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001459">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">284776628</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001461"
      unitRef="USD">2543059</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">287319687</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001469">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">14100000</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001473">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">-5420</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001481"
      unitRef="USD">-5420</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001495"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001497"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001507"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001509"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001513"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001515"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001517"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001521"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001523">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zHGfCbGDFHJ"&gt;Concentration of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001527">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zDDHritlLFyi"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;














</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001535">&lt;p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_869_zOCJzQXdOYs6"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001537">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zJiXM6UsbELc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cik0002065779:InitialPublicOfferingDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001539">&lt;p id="xdx_800_ecustom--InitialPublicOfferingDisclosureTextBlock_zxUzX7SDLfn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 3. &lt;span id="xdx_82D_zIv3avamgFu2"&gt;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziiKEuBh8qWg" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; Units, at $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7BSNxGdjR2d" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7xJdTWIQs8j" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt;. The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zi3AGJrNogke" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zaK7CJ35Z6P" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zdx2OOuJjDy3" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zzL7qvdcW5v5" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zywvxCggRqMi" title="Share price"&gt;11.50&lt;/span&gt; per share, subject to adjustment.&lt;/p&gt;












</cik0002065779:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001541"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001543"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001551"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">11.50</us-gaap:SharePrice>
    <cik0002065779:PrivatePlacementDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001562">&lt;p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zNIFkS0LzBs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 4. &lt;span id="xdx_828_zdpqfBsTh2A9"&gt;PRIVATE PLACEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpVriUo9y18" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; Private Units at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zF0n5WVwkcP5" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Placement Unit raising $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zld7xUyBfm51" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; in the aggregate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:PrivatePlacementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001564"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001566"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001568"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001570">&lt;p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpNHGTe8sIDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 5. &lt;span id="xdx_82C_z82mcy6I8tZ8"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Founder Shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On March&#160;25, 2025, the Company issued an aggregate
of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zMVgGcUrVxOe"&gt;12,321,429
&lt;/span&gt;founder shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_z6RLEudCp3Uj"&gt;25,000
&lt;/span&gt;in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August 11,
2025, on September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option
and thereby forfeit the option. As a result, on September 9, 2025, the Company cancelled a total of &lt;span id="xdx_909_ecustom--CancelledFounderShares_c20250905__20250909_zTcSZxGrsg3e" title="Cancelled founder shares"&gt;321,429
&lt;/span&gt;founder shares. As of March&#160;31, 2026, sponsor held a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zF5BsS2pB1Sd"&gt;12,000,000
&lt;/span&gt;founder shares and none was subject to forfeiture.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The founder shares are designated as Class B
ordinary shares and, except as described below, are identical to the Class A ordinary shares included in the units being sold in the
IPO, and holders of founder shares have the same shareholder rights as public shareholders, except that (i) the founder shares are
subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are entitled to registration
rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed
to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection with the
completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and
articles of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem &lt;span id="xdx_90D_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20260101__20260331_zXCLnhDFZiBd" title="Percentage of redemption of public shares"&gt;100&lt;/span&gt;%
of our public shares if we have not consummated an initial business combination within the completion window or (b) with respect to
any other material provisions relating to shareholders&#x2019; rights or pre-initial business combination activity, (C) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail to
complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within
such time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them
and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial
business combination (except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5
under the Exchange Act would not be voted in favor of approving the business combination transaction), (iv) the founder shares are
automatically convertible into Class A ordinary shares concurrently with or immediately following the consummation of our initial
business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in
our amended and restated memorandum and articles of association, and (v) prior to the closing of our initial business combination,
only holders of our Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing the
company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend our constitutional
documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation in
a jurisdiction outside the British Virgin Islands).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;With certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion of our initial business combination.&lt;/p&gt;




















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Administrative Services Arrangement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;An affiliate of our Sponsor has agreed, commencing
from the date that the Company&#x2019;s securities are first listed on Nasdaq, through the earlier of the Company&#x2019;s consummation
of a Business Combination and its liquidation, to make available to the Company our Sponsor certain office space, utilities and secretarial
and administrative support as may be reasonably required by the Company. The Company has agreed to pay to the affiliate of our Sponsor,
$&lt;span id="xdx_90C_eus-gaap--PaymentsOfDistributionsToAffiliates_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zQldRVTZCDxg"&gt;20,000
&lt;/span&gt;per month, for up to 18 months, subject to extension to up to 21 months, for such administrative services. For the three months ended March&#160;31, 2026, $&lt;span id="xdx_908_eus-gaap--AdministrativeFeesExpense_c20260101__20260331_zjj5mvpwbgkc"&gt;60,000
&lt;/span&gt; was charged to operations and no amounts were outstanding at March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Related Party Loans&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In order to finance transaction costs in connection with a Business Combination, the Company&#x2019;s Sponsor or an affiliate of the Sponsor, or the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Up to $&lt;span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z58fA98SjFOl" title="Conversion of debt"&gt;2,500,000&lt;/span&gt; of such loans may be convertible into private units, at a price of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuLJDC7MopX3" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit, at the option of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March&#160;31, 2026, no amounts under such loans have been drawn.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Representative Shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;1, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z6QXz08pyPJ3" title="Number of share issued"&gt;1,000,000&lt;/span&gt;
representative shares to D. Boral Capital, LLC and/or its designees (whether or not the over-allotment is exercised) as part of
representative compensation (the &#x201c;Representative Shares&#x201d;). The Representative Shares have been deemed compensation by
FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the IPO
pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold, transferred, assigned,
pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the
economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial Public
Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in the
Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale
registration rights including two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and
unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001571"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001572"
      unitRef="USD">25000</us-gaap:Cash>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001574"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">12000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Ratio">1</cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">20000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">60000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001588"
      unitRef="USD">2500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001590"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001592"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001594">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3K0SX2d4Sw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_82F_zdVOlujD2uBh"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Registration Rights&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii) Private Units (including the component securities as well as any securities underlying those component securities), which was issued in a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights granted to the underwriter are limited to two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Underwriting Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company has granted the underwriters a 45-day option to purchase up to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjtEhPvhMXQe" title="Option granted"&gt;3,750,000&lt;/span&gt; additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On August 11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR7wbwMpc9wh" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGqMeTvcqykf" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbSfvKxgSk01" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled to &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zFQcKs3SbWef" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters will not be entitled to any deferred underwriting fee upon closing of the Business Combination.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001603"
      unitRef="Shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001605"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001607"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001609"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001613">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwhUP6jv9mqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 7. &lt;span id="xdx_823_zaILIlDlzmsc"&gt;STOCKHOLDER&#x2019;S EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Preference shares&lt;/i&gt; &#x2014; The Company is
authorized to issue &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331_zFMVgjM8NmY9" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20251231_z0Jl6MArvzB9" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;
preference shares with a par value of $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331_zAytd7i2p886" title="Preferred stock, par value"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zfL19UEBgrDa" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
per share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025 and
March&#160;31, 2026, there were &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_zroPfs1eRoNk" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_z9d8GSit2B5" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zMEOzupxxnI8" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zyzADJxkUXd2" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
preferred shares issued or outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Class A Ordinary shares&lt;/i&gt; &#x2014; The
Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zKveQpajq4V5"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zskfIMqX190e"&gt;500,000,000&lt;/span&gt; &lt;/span&gt;ordinary
shares with a par value of $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zdRFWPvGhFOd"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zjY855rQwcpd"&gt;0.0001&lt;/span&gt; &lt;/span&gt;per
share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and
the partial exercise of the over-allotment option partial exercise of the over-allotment option, on December&#160;31, 2025 and March&#160;31,
2026, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxB3PXFsHCU5"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zsLdgforxL9e"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxt2nAqbsMr9"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z4vLyiaVVyR6"&gt;1,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;Class
A ordinary shares issued or outstanding, excluding &lt;span id="xdx_904_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinaryShareMember_zMl1aYF2ihsk"&gt;&lt;span id="xdx_90C_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zVJMl0G8IzV"&gt;28,000,000&lt;/span&gt; &lt;/span&gt;Class
A ordinary shares subject to possible redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Class B Ordinary shares&lt;/i&gt; &#x2014; The
Company is authorized to issue &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zXVGRwMjVDql"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zMMZnne8IkL6"&gt;50,000,000&lt;/span&gt; &lt;/span&gt;ordinary
shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_ztG2sNw8sNFl"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zED6jktrmjAl"&gt;0.0001&lt;/span&gt; &lt;/span&gt;per
share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company
issued an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zRVwJpN6yZVk"&gt;12,321,429 &lt;/span&gt;ordinary
shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250325_zAFxq56sMRg6"&gt;25,000 &lt;/span&gt;in
cash, of which &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_znPFdJkwaY27"&gt;1,607,143 &lt;/span&gt;shares
held by the Sponsor are subject to forfeiture to the extent that the underwriter&#x2019;s over-allotment option is not exercised in
full. Following the partial exercise of the over-allotment option on August 11, 2025 and cancellation &lt;span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zKYsRghvexAh" title="Cancellation of ordinary shares"&gt;321,429&lt;/span&gt;
ordinary shares on September 9, 2025, on December&#160;31, 2025 and March&#160;31, 2026, there were &lt;span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zKBpaz3TRFH" title="Common stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zIOANVibuum3" title="Common stock, shares outstanding"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;
ordinary &lt;span style="display: none"&gt;12,300,000&lt;/span&gt;shares issued and outstanding.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, &lt;span id="xdx_909_ecustom--PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_iI_dp_c20260331__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ConversionOfClassBToClassACommonStockMember_zszikt6CRcY8" title="Percentage of total number of ordinary shares"&gt;30&lt;/span&gt;% of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary shares issued pursuant to the underwriters&#x2019; over-allotment option and excluding the Class A ordinary shares that are included within the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial business combination; provided that such conversion of founder shares will never occur on a less than &lt;span id="xdx_903_eus-gaap--CommonStockConversionBasis_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zkHKuUlOOCQg" title="Conversion basis"&gt;one-for-one basis&lt;/span&gt;.&lt;/p&gt;





















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Holders of record of the Company&#x2019;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally required to approve any matter voted on by the Company&#x2019;s shareholders. Approval of certain actions require an ordinary resolution under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting, and pursuant to the Company&#x2019;s amended and restated memorandum and articles of association, such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#x2019;s initial Business Combination, the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at least 90% of the issued Class B ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Warrants &#x2014; &lt;/i&gt;Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. The Warrants will become exercisable &lt;span id="xdx_90C_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20260101__20260331_zWeApScMc3eb" title="Period of warrants exercisable"&gt;30&lt;/span&gt; days after the completion of our initial business combination, provided that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company may call the Warrants for redemption:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;in whole and not in part;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;at a price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoNP9mOnjT3c" title="Warrant price"&gt;0.01&lt;/span&gt; per warrant; upon a minimum of &lt;span id="xdx_90D_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20260101__20260331_zOnTLMGfRTZ7" title="Holders of warrants"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption (the &#x201c;30-day redemption period&#x201d;); and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;if, and only if, the closing price of the Class A ordinary shares equals or exceeds $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zJ9mqOJX3QCl" title="Share price"&gt;18.00&lt;/span&gt; per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any &lt;span id="xdx_900_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zvrNRerpdBn3" title="Number of trading days"&gt;20&lt;/span&gt; trading days within a &lt;span id="xdx_906_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zwbDb1yUTWP9" title="Number of consecutive trading days"&gt;30&lt;/span&gt;-trading day period commencing at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption to the warrant holders.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;






















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees, the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the &lt;span id="xdx_905_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zc5q1DDThXIl" title="Number of trading days"&gt;20&lt;/span&gt; trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the &#x201c;Market Value&#x201d;) is below $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331_zs54CHaUkD4i" title="Warrants exercise price"&gt;9.20&lt;/span&gt; per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_904_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20260331_zv6Vv7qifSKb" title="Market value"&gt;115&lt;/span&gt;% of the higher of the Market Value and the Newly Issued Price, and the $&lt;span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260331_zBQoRodwKOZj" title="Redemption price"&gt;18.00&lt;/span&gt; per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20260331_zxXMTxXeNMw5" title="Share redemption trigger prices"&gt;180&lt;/span&gt;% of the higher of the Market Value and the Newly Issued Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001617"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001619"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001623"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001625"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001627"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001629"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001630"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001631"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001632"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001633"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001634"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001636"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001637"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001638"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001639"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001640"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001641"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001642"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001644"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">25000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001646"
      unitRef="Shares">1607143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cik0002065779:CancellationOfOrdinaryShares
      contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001648"
      unitRef="Shares">321429</cik0002065779:CancellationOfOrdinaryShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001650"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001652"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion
      contextRef="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001654"
      unitRef="Ratio">0.30</cik0002065779:PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001656">one-for-one basis</us-gaap:CommonStockConversionBasis>
    <cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001665">P30D</cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001667"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001669">P30D</cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001671"
      unitRef="USDPShares">18.00</us-gaap:SharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001673">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001675">P30D</cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001683">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001685"
      unitRef="USDPShares">9.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001687"
      unitRef="Ratio">1.15</us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001689"
      unitRef="USDPShares">18.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <cik0002065779:ShareRedemptionTriggerPrices
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001691"
      unitRef="Ratio">1.80</cik0002065779:ShareRedemptionTriggerPrices>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001693">&lt;p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zgzIFlKymks6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 8. &lt;span id="xdx_822_zoFua9dYO0U2"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The following table presents information about
the Company&#x2019;s assets that are measured at fair value as of March 31, 2026 and December&#160;31, 2025, and indicates the fair
value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zvKnFHZJudo8" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March&#160;31,&lt;br/&gt;
    2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%"&gt;287,319,687&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zgzxRXAizoPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001696">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zvKnFHZJudo8" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March&#160;31,&lt;br/&gt;
    2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%"&gt;287,319,687&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001697"
      unitRef="USD">284776628</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001698"
      unitRef="USD">287319687</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001703">&lt;p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zwZU5ZaBhVlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 9. &lt;span&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_822_zUpXgs0k561c" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s chief operating decision maker has been identified as the Chief Financial Officer (&#x201c;CODM&#x201d;), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;When evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BC_zLnzHUlq4rs8" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the&lt;br/&gt;
Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Formation and operating costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(531,741&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on cash held in trust account&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWjH3W0mD6S6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The key measures of segment profit or loss reviewed
by the CODM are formation and operating costs, interest income on cash held in trust account, and cash held in trust account. The CODM
reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder value and determine the most effective
strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. Within the operating expenses,
the CODM specifically reviews professional service fees, which are a significant segment expense, and include legal fees and advisory
fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination within the required period.
Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed
in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account represent the predominant
portion of the Company&#x2019;s total assets and are monitored by the CODM to determine the most effective strategy of investment with
the Trust Account funds, while maintaining compliance with the trust agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001705">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BC_zLnzHUlq4rs8" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the&lt;br/&gt;
Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Formation and operating costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(531,741&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on cash held in trust account&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">531741</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001709"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <cik0002065779:CashHeldInTrustAccounts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001711"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccounts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001713">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zi2Xqda1MaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 10. &lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_829_zMAhencS9Vr8" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In accordance with ASC Topic 855, &#x201c;Subsequent Events&#x201d;, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred through the date the consolidated condensed financial statements were available to issue. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">969626</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001722"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001724"
      unitRef="USD">123332</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">152536</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">280497</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001728"
      unitRef="USD">1030761</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001730"
      unitRef="USD">110000</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001731"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001733"
      unitRef="USD">2884694</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001734"
      unitRef="USD">1207626</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001736"
      unitRef="USD">4368149</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001737"
      unitRef="USD">7303737</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001742"
      unitRef="USD">23696</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001743"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">23696</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">19600</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001748"
      unitRef="USD">4391845</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">7323337</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001757"
      unitRef="USD">128040</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001758"
      unitRef="USD">90015</us-gaap:AccountsPayableCurrent>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001760"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001761"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">95326</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001764"
      unitRef="USD">432760</us-gaap:DepositContractsLiabilities>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001766"
      unitRef="USD">223205</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001769"
      unitRef="USD">113693</cik0002065779:OtherCurrentLiabilities>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">107481</cik0002065779:OtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001772"
      unitRef="USD">9881828</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001773"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001775"
      unitRef="USD">9881828</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">20319721</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001787"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001789"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001791"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001793"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001801"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001784"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001785"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001803"
      unitRef="USD">67370</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">-5557368</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001807"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001809"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">4391845</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001813"
      unitRef="USD">7323337</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001815"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001818"
      unitRef="USD">-1263548</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001819"
      unitRef="USD">-5910315</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">55567</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">1105197</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001827"
      unitRef="USD">262614</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">989155</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001830"
      unitRef="USD">273349</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001831"
      unitRef="USD">362982</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">1365433</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001834"
      unitRef="USD">2797906</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001836"
      unitRef="USD">1901396</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">4150043</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">-1845829</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001840"
      unitRef="USD">-3044846</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001842"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001843"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">-4956347</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001846"
      unitRef="USD">-7659667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001851"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001852"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001857"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001859"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001861"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001863"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001868"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001870"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001872"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001874"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001881"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001876"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">46266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001878"
      unitRef="USD">-601021</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">-554740</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001886"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001889"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001891"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001898"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001893"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001894"
      unitRef="USD">67370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001895"
      unitRef="USD">-5557368</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001896"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001902"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001903"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001908"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001910"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001911"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001912"
      unitRef="USD">-13217035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001913"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001920"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001921"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001926"
      unitRef="USD">4110</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001927"
      unitRef="USD">6234</us-gaap:Depreciation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001929"
      unitRef="USD">21104</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001930"
      unitRef="USD">153266</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001932"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001933"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">123332</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001939"
      unitRef="USD">29204</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001941"
      unitRef="USD">280497</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001942"
      unitRef="USD">750264</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001944"
      unitRef="USD">100000</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001945"
      unitRef="USD">571125</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001947"
      unitRef="USD">-1515306</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001948"
      unitRef="USD">-1709568</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001950"
      unitRef="USD">128040</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001951"
      unitRef="USD">-38025</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001953"
      unitRef="USD">95326</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001954"
      unitRef="USD">337434</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001956"
      unitRef="USD">223205</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001957"
      unitRef="USD">1222375</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001959"
      unitRef="USD">-198342</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001960"
      unitRef="USD">-6212</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001962"
      unitRef="USD">-560909</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001963"
      unitRef="USD">-1010799</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001968"
      unitRef="USD">27806</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001969"
      unitRef="USD">2138</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001971"
      unitRef="USD">-27806</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001972"
      unitRef="USD">-2138</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001977"
      unitRef="USD">1285000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001978"
      unitRef="USD">4275000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001980"
      unitRef="USD">1285000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001981"
      unitRef="USD">4275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001983"
      unitRef="USD">696285</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001984"
      unitRef="USD">3262063</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001986"
      unitRef="USD">273341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001989"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001990"
      unitRef="USD">4231689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesAssumed1
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002004"
      unitRef="USD">4400000</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">32500</us-gaap:NotesAssumed1>
    <us-gaap:NatureOfOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002007">&lt;p id="xdx_80E_eus-gaap--NatureOfOperations_zPEtwaHe5HV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;1. &lt;span id="xdx_821_zp6MNea2BKv9"&gt;Organization and principal activities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June&#160;1, 2022, Exascale Labs Inc. (the &#x201c;Company&#x201d;)
was formally incorporated in the State of Delaware. In accordance with the Company&#x2019;s Certificate of Incorporation, the Company is
authorized to issue &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220601_zokPjcfKfLZ4" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; shares of ordinary shares, with a par value of $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220701_zXzvDlrClWQ5" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share, all in a single class. The governance structure
of the Company stipulates that the business and affairs of the Company shall be managed by or under the direction of its board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#x2019;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s
equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20)
votes per share, respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other
respects, sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding Simple Agreements for Future
Equity (&#x201c;SAFEs&#x201d;) are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company entered into an
Agreement and Plan of Merger (&#x201c;BCA&#x201d;) with D. Boral ARC Acquisition I Corp.(&#x201c;BCAR&#x201d;), a publicly traded special
purpose acquisition company (&#x201c;SPAC&#x201d;), D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary
of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction,
the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#x201c;PubCo&#x201d;) and is expected to be traded
on a national securities exchange.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-06-01_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002009"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-01_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002011"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002013">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zly3FShCFXe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;2. &lt;span id="xdx_826_znoSd0puRsll"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;a. &lt;span id="xdx_864_z1YlhGMWNLQ3"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents"&gt;4,231,689&lt;/span&gt;
and current liabilities of $20.3 &lt;span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities"&gt;20,319,721&lt;/span&gt;
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 &lt;span title="Net losses"&gt;&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities"&gt;(560,909)&lt;/span&gt;
million and $1.0 &lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities"&gt;(1,010,799)&lt;/span&gt;
million in cash for operating activities, and incurred net losses of $5.0 &lt;span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses"&gt;(4,956,347)&lt;/span&gt;
million and $7.7 &lt;span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses"&gt;(7,659,667)&lt;/span&gt;
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit"&gt;(13,217,035)&lt;/span&gt; million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern
within one year of the date these financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection with the Company&#x2019;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of this disclosure, &#x201c;SPAC&#x201d;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#x2019;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#x2019;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;b. &lt;span id="xdx_863_zpBEwXbVSFgl"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;c. &lt;span id="xdx_86E_zKFaeK3WfP28"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;d. &lt;span id="xdx_86B_zgmcgXMRrdyd"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;In accordance
with FASB ASC 820&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;/i&gt;&lt;span style="color: #212529; color: #212529"&gt;,
&lt;/span&gt;fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. &lt;span style="color: #212529; color: #212529"&gt;The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). &lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and &lt;/span&gt;cash equivalents&lt;span style="color: #212529; color: #212529"&gt;,
accounts receivable, r&lt;/span&gt;efundable deposits receivable, other receivables, &lt;span style="color: #212529; color: #212529"&gt;accounts payable,
r&lt;/span&gt;efundable deposits payable &lt;span style="color: #212529; color: #212529"&gt;and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;e. &lt;span id="xdx_865_zAyE0XfHmhD6"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements are presented
in the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All transactions are measured and recorded in the
Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;f. &lt;span id="xdx_863_zISAmbUCaane"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does &lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have
any cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;g. &lt;span id="xdx_867_zsUZxth16ncb"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company adopted Financial Standards Accounting
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit
Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;h. &lt;span id="xdx_86C_zgfztbsMVxIj"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;i. &lt;span id="xdx_86D_z7CffKljqsfj"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the balances were
$&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable"&gt;110,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable"&gt;681,125&lt;/span&gt;, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was &lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;j. &lt;span id="xdx_86F_zf8ptRHzRO28"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;k. &lt;span id="xdx_86E_zLIGi7CATnu7"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was &lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;l. &lt;/i&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;&lt;span id="xdx_867_z4BrJrohRAA9"&gt;Simple
agreements for future equity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;m. &lt;span id="xdx_86E_zA2yNWLqfBFd"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019; credit profiles and service
requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(i) Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous access to a functioning
and secured platform over the contractual term.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reserved capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On-demand (pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(ii) Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#x2019;s services are performed throughout
the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the&#160;years ended June&#160;30, 2024 and 2025,
$&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue"&gt;1,319,115&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue"&gt;7,015,512&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;n. &lt;span id="xdx_864_zhAHETYm7uU4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#x201c;Contract
liabilities&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil &lt;span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; for the years ended June&#160;30, 2024 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;o. &lt;span id="xdx_868_zt2YqZ7h4862"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;p. &lt;span id="xdx_861_z8U06Sm8eK8b"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses"&gt;26,340&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses"&gt;157,388&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;q. &lt;span id="xdx_864_zLpo4DODnKa5"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s research and development expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software development outsourcing service fees and testing expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;r. &lt;span id="xdx_866_z1OzlN0cGTed"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s general and administrative expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;s. &lt;span id="xdx_86A_zfzDgxosnhkd"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are determined in accordance with the
provisions of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC Topic 740&#x201d;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;t. &lt;span id="xdx_86F_zOYxMEHi9sP1"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt;&lt;/span&gt; ordinary
shares of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; par value each. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated to &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt;
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;u. &lt;span id="xdx_860_zz7zMNdlRtT9"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employees&#x2019; share-based awards and non-employees&#x2019;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;v. &lt;span id="xdx_867_zetDcyDJZsD4"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 280, &#x201c;Segment Reporting&#x201d;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#x2019;s
business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;) for making operating decisions and assessing performance as the source for determining
the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#x2019;s performance and results of operations on an entity-wide basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;w. &lt;span id="xdx_862_zI2bQw1nSKC"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;x. &lt;span id="xdx_866_zJfxnr89HArh"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#x2019;s comprehensive
loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;y.&lt;span id="xdx_864_zWpJBAyOYapg"&gt; Loss&#160;per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;z. &lt;span id="xdx_86E_z1wQVhVX3E9i"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dividends are recognized when declared. &lt;span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"&gt;&lt;span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;aa. &lt;span id="xdx_86F_zUUr7JvI51i1"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June&#160;2016, the FASB issued ASU&#160;2016-13,
&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt; (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;).
The new accounting standard introduced the current expected credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#x2019;s
statements of income, or statements of cash flows.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#x201c;Segment Reporting (Topic&#160;280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;.&#x201d; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#x201c;CODM&#x201d;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;bb. &lt;span id="xdx_860_zodYVIxzme09"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company intends to operate as an &#x201c;emerging
growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#x2019;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;cc. &lt;span id="xdx_86D_z61KGdSvMHp3"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements
to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#x2019;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU No. 2024-02,
&lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt; (&#x201c;ASU 2024-02&#x201d;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU 2024-03
&#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update intend to improve the disclosures about
a public business entity&#x2019;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive (loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt;
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cik0002065779:GoingConcernPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002015">&lt;p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;a. &lt;span id="xdx_864_z1YlhGMWNLQ3"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents"&gt;4,231,689&lt;/span&gt;
and current liabilities of $20.3 &lt;span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities"&gt;20,319,721&lt;/span&gt;
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 &lt;span title="Net losses"&gt;&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities"&gt;(560,909)&lt;/span&gt;
million and $1.0 &lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities"&gt;(1,010,799)&lt;/span&gt;
million in cash for operating activities, and incurred net losses of $5.0 &lt;span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses"&gt;(4,956,347)&lt;/span&gt;
million and $7.7 &lt;span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses"&gt;(7,659,667)&lt;/span&gt;
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit"&gt;(13,217,035)&lt;/span&gt; million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern
within one year of the date these financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection with the Company&#x2019;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of this disclosure, &#x201c;SPAC&#x201d;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#x2019;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#x2019;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:GoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002017"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002019"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002021"
      unitRef="USD">-560909</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002023"
      unitRef="USD">-1010799</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002025"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002029"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002036">&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;b. &lt;span id="xdx_863_zpBEwXbVSFgl"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002038">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;c. &lt;span id="xdx_86E_zKFaeK3WfP28"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002040">&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;d. &lt;span id="xdx_86B_zgmcgXMRrdyd"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;In accordance
with FASB ASC 820&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;/i&gt;&lt;span style="color: #212529; color: #212529"&gt;,
&lt;/span&gt;fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. &lt;span style="color: #212529; color: #212529"&gt;The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). &lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and &lt;/span&gt;cash equivalents&lt;span style="color: #212529; color: #212529"&gt;,
accounts receivable, r&lt;/span&gt;efundable deposits receivable, other receivables, &lt;span style="color: #212529; color: #212529"&gt;accounts payable,
r&lt;/span&gt;efundable deposits payable &lt;span style="color: #212529; color: #212529"&gt;and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <cik0002065779:FunctionalCurrencyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002047">&lt;p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;e. &lt;span id="xdx_865_zAyE0XfHmhD6"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements are presented
in the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All transactions are measured and recorded in the
Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002049">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;f. &lt;span id="xdx_863_zISAmbUCaane"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does &lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have
any cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002051"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002053"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002055">&lt;p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;g. &lt;span id="xdx_867_zsUZxth16ncb"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company adopted Financial Standards Accounting
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit
Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock>
    <cik0002065779:AdvanceToSuppliersPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002060">&lt;p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;h. &lt;span id="xdx_86C_zgfztbsMVxIj"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:AdvanceToSuppliersPolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivablePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002062">&lt;p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;i. &lt;span id="xdx_86D_z7CffKljqsfj"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the balances were
$&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable"&gt;110,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable"&gt;681,125&lt;/span&gt;, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was &lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsReceivablePolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002064"
      unitRef="USD">110000</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002066"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002068"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002070"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002072">&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;j. &lt;span id="xdx_86F_zf8ptRHzRO28"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002074">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;k. &lt;span id="xdx_86E_zLIGi7CATnu7"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was &lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002076"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002078"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002080">&lt;p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;l. &lt;/i&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;&lt;span id="xdx_867_z4BrJrohRAA9"&gt;Simple
agreements for future equity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002085">&lt;p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;m. &lt;span id="xdx_86E_zA2yNWLqfBFd"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019; credit profiles and service
requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(i) Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous access to a functioning
and secured platform over the contractual term.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reserved capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On-demand (pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(ii) Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#x2019;s services are performed throughout
the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the&#160;years ended June&#160;30, 2024 and 2025,
$&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue"&gt;1,319,115&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue"&gt;7,015,512&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









</us-gaap:RevenueRecognitionDeferredRevenue>
    <cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002092">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002094"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002096"
      unitRef="USD">6501569</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002100"
      unitRef="USD">44680</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002102"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002104"
      unitRef="USD">6546249</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002106"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002108"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002110">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002112"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002114"
      unitRef="USD">6546249</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002116"
      unitRef="USD">125133</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002118"
      unitRef="USD">469263</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002120"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002122"
      unitRef="USD">7015512</us-gaap:Revenues>
    <cik0002065779:ContractLiabilitiesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002127">&lt;p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;n. &lt;span id="xdx_864_zhAHETYm7uU4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#x201c;Contract
liabilities&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil &lt;span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; for the years ended June&#160;30, 2024 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ContractLiabilitiesPolicyTextBlock>
    <cik0002065779:RevenueRecognized
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002129"
      unitRef="USD">0</cik0002065779:RevenueRecognized>
    <cik0002065779:RevenueRecognized
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002131"
      unitRef="USD">95326</cik0002065779:RevenueRecognized>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002133">&lt;p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;o. &lt;span id="xdx_868_zt2YqZ7h4862"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <cik0002065779:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002135">&lt;p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;p. &lt;span id="xdx_861_z8U06Sm8eK8b"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses"&gt;26,340&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses"&gt;157,388&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SellingAndMarketingExpensesPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002137"
      unitRef="USD">26340</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002139"
      unitRef="USD">157388</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002141">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;q. &lt;span id="xdx_864_zLpo4DODnKa5"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s research and development expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software development outsourcing service fees and testing expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002143">&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;r. &lt;span id="xdx_866_z1OzlN0cGTed"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s general and administrative expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002145">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;s. &lt;span id="xdx_86A_zfzDgxosnhkd"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are determined in accordance with the
provisions of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC Topic 740&#x201d;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <cik0002065779:CapitalStructurePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002150">&lt;p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;t. &lt;span id="xdx_86F_zOYxMEHi9sP1"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt;&lt;/span&gt; ordinary
shares of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; par value each. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated to &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt;
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CapitalStructurePolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002152"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002154"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002156"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002158"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002160"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002162"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002164"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002166"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002168"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002170"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002172"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002174">&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;u. &lt;span id="xdx_860_zz7zMNdlRtT9"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employees&#x2019; share-based awards and non-employees&#x2019;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002176">&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;v. &lt;span id="xdx_867_zetDcyDJZsD4"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 280, &#x201c;Segment Reporting&#x201d;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#x2019;s
business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;) for making operating decisions and assessing performance as the source for determining
the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#x2019;s performance and results of operations on an entity-wide basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cik0002065779:RelatedPartiesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002181">&lt;p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;w. &lt;span id="xdx_862_zI2bQw1nSKC"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RelatedPartiesPolicyTextBlock>
    <cik0002065779:ComprehensiveLossPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002183">&lt;p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;x. &lt;span id="xdx_866_zJfxnr89HArh"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#x2019;s comprehensive
loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ComprehensiveLossPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002185">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;y.&lt;span id="xdx_864_zWpJBAyOYapg"&gt; Loss&#160;per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueRecognitionDividends
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002187">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;z. &lt;span id="xdx_86E_z1wQVhVX3E9i"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dividends are recognized when declared. &lt;span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"&gt;&lt;span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDividends>
    <us-gaap:Dividends
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002189"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">0</us-gaap:Dividends>
    <cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002193">&lt;p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;aa. &lt;span id="xdx_86F_zUUr7JvI51i1"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June&#160;2016, the FASB issued ASU&#160;2016-13,
&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt; (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;).
The new accounting standard introduced the current expected credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#x2019;s
statements of income, or statements of cash flows.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#x201c;Segment Reporting (Topic&#160;280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;.&#x201d; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#x201c;CODM&#x201d;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002200">&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;bb. &lt;span id="xdx_860_zodYVIxzme09"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company intends to operate as an &#x201c;emerging
growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#x2019;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002202">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;cc. &lt;span id="xdx_86D_z61KGdSvMHp3"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements
to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#x2019;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU No. 2024-02,
&lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt; (&#x201c;ASU 2024-02&#x201d;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU 2024-03
&#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update intend to improve the disclosures about
a public business entity&#x2019;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive (loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt;
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002209">&lt;p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCNDhVCVmNLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;3. &lt;span id="xdx_82C_zFBbZ0r7Zud1"&gt;Concentration and risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject us
to concentrations of credit risk consisted primarily of cash and cash equivalents, and accounts receivable. We perform ongoing credit
evaluations of our customers&#x2019; financial condition and maintain an allowance for potential credit losses. This allowance consisted
of an amount identified for specific customers and an amount based on overall estimated exposure. Our overall estimated exposure excludes
amounts covered by credit insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s revenue was concentrated among
a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the total
revenue:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk"&gt;12.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk"&gt;14.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2217"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk"&gt;12.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk"&gt;31.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk"&gt;11.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk"&gt;11.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zXQpMtPkMqqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s account receivable was concentrated
among a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the
total account receivable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer G&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk"&gt;23.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk"&gt;43.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk"&gt;15.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for as of June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zazzTEdf3qC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s purchases was concentrated among
a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the total
purchase:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk"&gt;56.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk"&gt;41.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk"&gt;14.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk"&gt;31.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk"&gt;18.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk"&gt;12.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zNVjriFteaE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s account payable was concentrated
among a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the
total account payable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier E&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2282"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk"&gt;99.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zUoOBb8uOtB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002211">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk"&gt;12.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk"&gt;14.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2217"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk"&gt;12.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk"&gt;31.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk"&gt;11.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk"&gt;11.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002213"
      unitRef="Ratio">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002215"
      unitRef="Ratio">0.140</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002219"
      unitRef="Ratio">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002223"
      unitRef="Ratio">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002225"
      unitRef="Ratio">0.316</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002229"
      unitRef="Ratio">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002233"
      unitRef="Ratio">0.110</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfAccountsReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002242">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer G&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk"&gt;23.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk"&gt;43.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk"&gt;15.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for as of June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfAccountsReceivableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002246"
      unitRef="Ratio">0.427</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002250"
      unitRef="Ratio">0.383</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002252"
      unitRef="Ratio">0.234</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002254"
      unitRef="Ratio">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002256"
      unitRef="Ratio">0.435</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002260"
      unitRef="Ratio">0.153</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002262">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk"&gt;56.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk"&gt;41.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk"&gt;14.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk"&gt;31.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk"&gt;18.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk"&gt;12.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002264"
      unitRef="Ratio">0.566</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002266"
      unitRef="Ratio">0.414</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002268"
      unitRef="Ratio">0.146</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002270"
      unitRef="Ratio">0.317</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002274"
      unitRef="Ratio">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002276"
      unitRef="Ratio">0.128</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002280">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier E&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2282"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk"&gt;99.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002284"
      unitRef="Ratio">0.549</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002288"
      unitRef="Ratio">0.323</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002290"
      unitRef="Ratio">0.994</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002292"
      unitRef="Ratio">0.121</cik0002065779:ConcentrationRiskPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002295">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zZLKhN6jsn7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;4. &lt;span id="xdx_820_zfA52tDeRbgk"&gt;Fair value measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, information about
inputs into the fair value measurement of the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis
in periods subsequent to their initial recognition is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2309"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2319"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
        &lt;p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115"&gt;Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zHmdNJR8ytF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002297">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2309"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2319"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
        &lt;p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115"&gt;Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002299"
      unitRef="USD">9321564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002305"
      unitRef="USD">9321564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002307"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002313"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002315"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002321"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002323"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002329"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AccountsAndNontradeReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002334">&lt;p id="xdx_806_eus-gaap--AccountsAndNontradeReceivableTextBlock_zdje7HeU8Tqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;5. &lt;span id="xdx_826_z2cS9GvZHBdg"&gt;Accounts receivable &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: allowance for credit
        losses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Accounts
        receivable, net&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts Receivable are recorded at the invoiced amount
and do not bear interest. The Company maintains an allowance for credit losses for expected losses over the life of the accounts receivable
using the current expected credit loss methodology. The Company determines the allowance based on historical loss experience, current
conditions, and reasonable and supportable forecasts. As of June&#160;30, 2024 and 2025, there was &lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zNwMZQsRvRJ9" title="Allowance for credit losses"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z7pQLRmnRnl8" title="Allowance for credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002336">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: allowance for credit
        losses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Accounts
        receivable, net&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002338"
      unitRef="USD">123332</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002340"
      unitRef="USD">152536</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002342"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002346"
      unitRef="USD">123332</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002348"
      unitRef="USD">152536</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002350"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002352"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <cik0002065779:OtherReceivablesTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002354">&lt;p id="xdx_80A_ecustom--OtherReceivablesTextBlock_zA37jU1ZOfV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;br/&gt;&lt;b&gt;6. &lt;span id="xdx_821_zYjS7DyznEb5"&gt;Other receivables&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other receivables represent funds temporarily held
in trust by an employee acting as the Company&#x2019;s behalf. As of June&#160;30, 2024 and 2025, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_c20240630_pp0p" title="Other receivables"&gt;2,884,694&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherReceivables_c20250630_pp0p" title="Other receivables"&gt;1,207,626&lt;/span&gt;,
respectively, primary comprising proceeds from SAFEs agreements received via the employee &lt;span style="color: #0F1115; color: #0F1115"&gt;and
net of payments made to designated suppliers at the Company&#x2019;s direction. The outstanding balance was fully settled in January&#160;2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OtherReceivablesTextBlock>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002356"
      unitRef="USD">2884694</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002358"
      unitRef="USD">1207626</us-gaap:OtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002360">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zLYDRpyLKNhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;7. &lt;span id="xdx_820_z8sx4dTJBxsg"&gt;Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,110&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net
        carrying amount&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;23,696&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;19,600&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expenses for the&#160;years ended June&#160;30,
2024 and 2025 were $&lt;span id="xdx_900_eus-gaap--Depreciation_c20230701__20240630_zomGNXN2kYl4" title="Depreciation expenses"&gt;4,110&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_c20240701__20250630_zueTAB6r85N5" title="Depreciation expenses"&gt;6,234&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002362">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,110&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net
        carrying amount&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;23,696&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;19,600&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002364"
      unitRef="USD">27806</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002365"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002367"
      unitRef="USD">27806</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002368"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002370"
      unitRef="USD">4110</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002371"
      unitRef="USD">10344</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002373"
      unitRef="USD">23696</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002374"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002376"
      unitRef="USD">4110</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002378"
      unitRef="USD">6234</us-gaap:Depreciation>
    <cik0002065779:RefundableDepositsPayableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002380">&lt;p id="xdx_80D_ecustom--RefundableDepositsPayableTextBlock_zdT8v1NNaUXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;8. &lt;span id="xdx_82D_zslWpkq71Jm9"&gt;Refundable deposits payable &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits payable represent security payments
received from a third party and customers, which are required for certain intelligent computing power service arrangements. As of June&#160;30,
2024 and 2025, the balance were $&lt;span id="xdx_908_ecustom--RefundableDepositsPayable_c20240630_pp0p" title="Refundable deposits payable"&gt;223,205&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--RefundableDepositsPayable_c20250630_pp0p" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsPayableTextBlock>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002382"
      unitRef="USD">223205</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002384"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:SimpleAgreementsForFutureEquityTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002386">&lt;p id="xdx_803_ecustom--SimpleAgreementsForFutureEquityTextBlock_zOlXnvXLN6Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;9. &lt;span id="xdx_821_zGErECRHaUFh"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into SAFEs with various investors
that were classified as liabilities on the Company&#x2019;s balance sheets and accounted for at fair value, subject to remeasurement each
reporting period. Each SAFEs has no maturity date, does not bear any interest and provides the investor with the right to convert into
a variable number of shares of future equity in the Company at the stated conversion amount, if certain events or conditions are triggered.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period from October&#160;2022 through June&#160;2025,
the Company entered into Simple Agreements for Future Equity with third-party investors, receiving aggregate gross proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20221001__20250630_pp0p" title="Aggregate gross proceeds"&gt;10,592,500&lt;/span&gt;.
Of this amount, $&lt;span id="xdx_900_eus-gaap--ProceedsFromOtherEquity_c20230701__20240630_pp0p" title="Aggregate gross proceeds"&gt;5,685,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_c20240701__20250630_pp0p" title="Aggregate gross proceeds"&gt;4,307,500&lt;/span&gt; were recorded in the fiscal years ended June&#160;30, 2024 and 2025, respectively. Subsequent
to June&#160;30, 2025, the Company received additional SAFEs proceeds of $&lt;span id="xdx_905_ecustom--AdditionalSafesProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkdoR94mROG6" title="Additional SAFEs proceeds"&gt;500,000&lt;/span&gt;, resulting in cumulative proceeds of $&lt;span id="xdx_908_ecustom--CumulativeProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVj7nuUFaL8k" title="Cumulative proceeds"&gt;11,092,500&lt;/span&gt; as
of the date of this report. No issuance costs were incurred in connection with these arrangements. As of the date these financial statements
are issued, none of the SAFEs have been settled or converted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SAFEs agreements grant investors the right to
participate in the Company&#x2019;s future equity financing events. The agreements contain various conversion and redemption provisions,
including conversion upon an equity financing event, as well as settlement in the event of a liquidity event or dissolution of the Company.
Key terms of the SAFEs are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Equity Financing&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Upon the
occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the number of shares of preferred
stock equal to SAFEs purchase amount divided by &lt;span style="color: #0F1115; color: #0F1115"&gt;the lowest price per share paid for the standard
preferred stock&lt;/span&gt; or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;SAFEs price&#x201d; means &lt;span style="color: #0F1115; color: #0F1115"&gt;is
        calculated by dividing a fixed post-money valuation cap by the Company capitalization, a defined term that includes all outstanding equity
        and convertible instruments.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Equity Financing&#x201d; means a bona
        fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells
        preferred share at a fixed valuation, including but not limited to, a pre-money or post-money valuation.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Not all SAFEs agreements contain the equity financing
conversion provision described above. Certain SAFEs are structured without an Equity Financing conversion feature and are generally settled
only upon a Liquidity Event or a Dissolution Event (as defined in the respective SAFEs agreements). The Company considered the contractual
terms of the SAFEs, including whether an Equity Financing conversion feature is present and the settlement provisions upon a Liquidity
Event or a Dissolution Event, in the valuation and measurement of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, &lt;span id="xdx_90D_ecustom--EquityFinancingDescription_pp0d_c20240701__20250630_zpoJJ0lxxOh" title="Equity Financing description"&gt;SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
does not have any preferred stock outstanding as of February&#160;11, 2026; therefore, an equity financing event has not been triggered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there
is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to the greater of (i)
SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal to the purchase amount divided
by the Liquidity Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Liquidity Price&#x201d; is calculated
        by dividing the post-money valuation cap by the separately defined capital base, referred to as &#x201c;liquidity capitalization&#x201d;
        in the SAFEs agreements.&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Liquidity Event&#x201d; means a change
        of control, a direct Listing or an initial public offering.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Dissolution Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there
is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to receive a portion
of proceeds equal to SAFEs purchase amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
measured at fair value. Since the value of these instruments depends on significant unobservable inputs, including future financing activities
and liquidity events, they are classified as Level 3 within the fair value hierarchy.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement utilizes a combined scenario
analysis and financial instrument decomposition approach. Based on management&#x2019;s assessment of the Company&#x2019;s prospects, probability
distributions are assigned to potential settlement-triggering events. Valuation is performed using a &#x201c;debt plus option&#x201d; model:
the debt component is valued using a discounted cash flow method with key assumptions including expected settlement timing, risk-free
interest rate, and credit spread; the embedded conversion right is treated as a call option and valued using the Black-Scholes model,
with key inputs including the fair value of ordinary shares, expected term, and volatility. The overall fair value represents the probability-weighted
sum across all scenarios, supported by an independent third-party valuation specialist.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the SAFEs liabilities
were measured at fair value using the above Level 3 methodology. Significant unobservable inputs&#x2014;including timing of events, volatility,
and credit spreads&#x2014;are based on management&#x2019;s reasonable estimates as of each valuation date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables set forth a summary of the activity
of the SAFEs liabilities, respectively, which represents a recurring fair value measurement at the end of each reporting period:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt"&gt;Balance at
        June&#160;30, 2023&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning"&gt;526,046&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity"&gt;5,685,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value"&gt;3,110,518&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity"&gt;4,307,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value"&gt;4,614,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;If and
when the SAFEs are converted into equity, management currently expects that such conversion would be settled through transfers of existing
ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company, subject to the final
conversion terms and the relevant agreements. To the extent settled in this manner, the underlying ordinary shares are already included
in the Company&#x2019;s issued and outstanding shares as of the balance sheet date; therefore, such settlement would not be expected to
increase the Company&#x2019;s total issued and outstanding shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to June&#160;30, 2025 (see Note 1), in
connection with the proposed business combination, the outstanding SAFEs are expected to be settled upon the closing of the transaction
(the &#x201c;Closing&#x201d;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination of the SAFEs, each SAFE will
automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the Closing of BCA transaction, each of SAFEs is
expected to convert into the Class A shares of the PubCo without any action required by the SAFE holders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityTextBlock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-10-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002391"
      unitRef="USD">10592500</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002393"
      unitRef="USD">5685000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002395"
      unitRef="USD">4307500</us-gaap:ProceedsFromOtherEquity>
    <cik0002065779:AdditionalSafesProceeds
      contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002397"
      unitRef="USD">500000</cik0002065779:AdditionalSafesProceeds>
    <cik0002065779:CumulativeProceeds
      contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002399"
      unitRef="USD">11092500</cik0002065779:CumulativeProceeds>
    <cik0002065779:EquityFinancingDescription
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002401">SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.</cik0002065779:EquityFinancingDescription>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002406">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt"&gt;Balance at
        June&#160;30, 2023&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning"&gt;526,046&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity"&gt;5,685,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value"&gt;3,110,518&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity"&gt;4,307,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value"&gt;4,614,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002408"
      unitRef="USD">526046</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002410"
      unitRef="USD">5685000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002412"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002414"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002416"
      unitRef="USD">4307500</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002418"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002420"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002422">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zcy1yoqRg3A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;10. &lt;span id="xdx_829_zqCnxgL6N714"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company was incorporated in the State of Delaware
and is subject to income taxes in its primary jurisdictions: U.S. federal income tax and Delaware state corporate income tax. The statutory
tax rates applicable to the Company are &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20230701__20240630_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt; at the federal level and &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20230701__20240630_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt; at the Delaware state level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The current and deferred components of income tax
expense reflected in the statements of operations and comprehensive loss were nil for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reconciles the statutory rate
to the Company&#x2019;s effective tax rate. The effective tax rate reconciliation is based on the U.S. federal statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20240701__20250630_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt; and
State income tax rate of &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule
    of effective tax rate reconciliation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;US Statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;State income tax rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Change in fair value of simple agreements
        for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18.6&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Changes in valuation
        allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.1&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.8&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax
        rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zEYZ96HGd4s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s effective income tax rate was&#160;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20230701__20240630_pd" title="Effective income tax rate"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250630_pd" title="Effective income tax rate"&gt;0%&lt;/span&gt;&lt;/span&gt;&#160;for
both years ended June&#160;30, 2024 and 2025. This is primarily attributable to the&#160;recognition of a full valuation allowance against
the net deferred tax assets, as the Company has concluded that it is not more likely than not that these assets will be realized in the
foreseeable future. Accordingly, no tax benefit has been recognized for the losses incurred during these periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The principal components of deferred tax assets and
deferred tax liabilities were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of deferred tax assets liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,679&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,652,998&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total
        deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zuxWXyBw7azl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in valuation allowance for the years ended
June&#160;30, 2024 and 2025 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Balance at the beginning of the
        year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year"&gt;(200,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions"&gt;(548,211&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions"&gt;(904,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance
        at the end of the year&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year"&gt;(1,652,998&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z8CNIKlnZrV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the Company had
net operating loss carryforwards (&#x201c;NOLs&#x201d;) of $&lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zpz7739yT5vi" title="Net operating loss carryforwards"&gt;2.5 &lt;/span&gt;million and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zc5tGTGft7Zk" title="Net operating loss carryforwards"&gt;5.6&lt;/span&gt; million for U.S. federal income tax purposes and $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrcfQglwNFDb" title="Net operating loss carryforwards"&gt;2.5&lt;/span&gt; million
and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrvFbn738Xcg" title="Net operating loss carryforwards"&gt;5.6&lt;/span&gt; million for state income tax purposes.&#160;The federal NOLs&#160;do not expire but are subject to an annual deduction limit
of 80% of taxable income.&#160;The Company&#x2019;s NOLs can be carried forward to offset current year profit for Delaware corporate income
tax purposes, subject to certain limitations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes deferred tax assets if it is
more likely than not that those deferred tax assets will be realized. Management reviews deferred tax assets periodically for recoverability
and makes estimates and judgments regarding the expected geographic sources of taxable income in assessing the need for a valuation allowance
to reduce deferred tax assets to their estimated realizable value. Realization of the Company&#x2019;s deferred tax assets is dependent
upon future earnings, if any, the timing and amount of which are uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had &lt;span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20250630_zIwngjxvmio1" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20240630_zXcxlUP6ogpf" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of
June&#160;30, 2024 and 2025. The Company currently files income tax returns in the U.S., as well as Delaware. All tax years are open for
examination. The Company currently has no federal or state tax examinations in progress.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002424"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002426"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002431"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002433"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002435">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule
    of effective tax rate reconciliation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;US Statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;State income tax rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Change in fair value of simple agreements
        for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18.6&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Changes in valuation
        allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.1&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.8&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax
        rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002437"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002438"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002440"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002441"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002443"
      unitRef="Ratio">-0.186</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002444"
      unitRef="Ratio">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002446"
      unitRef="Ratio">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002447"
      unitRef="Ratio">-0.118</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002449"
      unitRef="Ratio">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002450"
      unitRef="Ratio">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002452"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002454"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002456">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of deferred tax assets liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,679&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,652,998&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total
        deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002461"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002462"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002464"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002465"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002467"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002468"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002473">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Balance at the beginning of the
        year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year"&gt;(200,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions"&gt;(548,211&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions"&gt;(904,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance
        at the end of the year&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year"&gt;(1,652,998&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002475"
      unitRef="USD">200468</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002477"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002479"
      unitRef="USD">-548211</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002481"
      unitRef="USD">-904319</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002483"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002485"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002487"
      unitRef="USD">2500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002489"
      unitRef="USD">5600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002491"
      unitRef="USD">2500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002493"
      unitRef="USD">5600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002495"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002497"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002500">&lt;p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zEMl0kz98Cb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;11. &lt;span id="xdx_82F_zojw0uTLGhUa"&gt;Share-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended June&#160;30, 2024 and 2025, total
share-based compensation expenses recognized were $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630_pp0p" title="Share-based compensation expenses"&gt;21,104&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630_pp0p" title="Share-based compensation expenses"&gt;153,266&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth the share-based compensation
expenses for the years ended June&#160;30, 2024 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of share-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;General and administrative
        expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January&#160;6, 2025, with the approval from the
Board of the Company, an employee was granted equity award from inception of the employment agreement, which represented 0.1% of the Company&#x2019;s
total shares outstanding at issuance date (the &#x201c;0.1% Award&#x201d;, i.e., 1.5 shares). The equity award had a vesting period of 24
months after grant, but with no requisite service period. Alongside with the employee&#x2019;s separation in September&#160;2025, the equity
award remained its vesting pace under the 24-month vesting schedule. As of June&#160;30, 2025, &lt;span id="xdx_907_ecustom--SharesDescription_pp0d_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_ziZsFKTjvi5i" title="Shares description"&gt;0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined January&#160;6, 2025 to be
the grant date of the 0.1% Award and recognized total share-based compensation expense amounted to $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Share-based compensation expenses"&gt;101,000&lt;/span&gt; at the grant date for the
award since the explicit service vesting condition is not the employee&#x2019;s requisite service period, and the vesting condition is
not a service condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on
the fair value of the 0.1% Award as of the grant date. The fair value of the 0.1% Award was determined with assistance of an independent
third-party valuation specialist using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Risk free rate"&gt;4.24%&lt;/span&gt;, discount rate of &lt;span id="xdx_900_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Discount rate"&gt;13.6%&lt;/span&gt;
and perpetual rate of &lt;span id="xdx_901_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Non-employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December&#160;2, 2024, with the approval from the
Board of the Company, a contractor was granted equity award from inception of the contractor agreement representing 0.053333% of the Company&#x2019;s
total shares outstanding at issuance date (&#x201c;0.05% Award&#x201d;, i.e., 0.8 shares). The equity award had a vesting period of 24 months
after grant, with half vested as of April&#160;1, 2025 and remaining as of November&#160;1, 2026, but with no requisite service period.
As of June&#160;30, 2025, the first half of the equity award had been vested, the remaining half had been outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined December&#160;2, 2024 to be
the grant date of the 0.05% Award and recognized total share-based compensation expense amounted to $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pp0p" title="Share-based compensation expenses"&gt;52,266&lt;/span&gt; at the grant date for the
award since the explicit service vesting condition is not the nonemployee&#x2019;s vesting period, and the vesting condition is not a service
condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on the fair value
of the 0.1% Award as of the grant date. The fair value of the 0.05% Award was determined with assistance of an independent third-party
valuation specialist using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Risk free rate"&gt;4.36%&lt;/span&gt;, discount rate of &lt;span id="xdx_90C_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Discount rate"&gt;14.9%&lt;/span&gt; and perpetual
rate of &lt;span id="xdx_90E_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May&#160;9, 2023, the Company entered into an agreement
with a third-party Service Provider to receive accelerator training services. In consideration for these services, the Company agreed
to grant the Service Provider equity equal to 0.425% of shares outstanding at issuance. The Company accounts for the award as consideration
for services in accordance with ASC 718, &lt;i&gt;Compensation&#x2014;Stock Compensation.&lt;/i&gt; The Company measures equity instruments granted
to a non-employee in exchange for services at their fair value on the grant date and engaged an independent third-party valuation specialist
to determine the grant-date fair value using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Risk free rate"&gt;3.81%&lt;/span&gt;, discount rate
of &lt;span id="xdx_906_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Discount rate"&gt;15.5%&lt;/span&gt; and perpetual rate of &lt;span id="xdx_904_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;. The related compensation cost is recognized as expense, with a corresponding increase to additional
paid-in capital, on a straight-line basis over the requisite service period during which the counterparty provides services, which was
from May&#160;2023 through July&#160;2023. For the year ended June&#160;30, 2024, the Company recognized $&lt;span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20230701__20240630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pp0p" title="General and administrative expense"&gt;21,104&lt;/span&gt;, which was recorded within
general and administrative expense in the statements of operations and comprehensive loss. The award was fully vested as of June&#160;30,
2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in the issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares. The vested
shares are not recorded in the individual names of the holders on the Company&#x2019;s stock ledger, but held by the controlling shareholder
on their behalf, mainly due to the plan to a direct register of shares under the listed company during de-SPAC transaction. The Company,
as well as the controlling shareholder deemed the grant as the time when the employee and non-employees are entitled to economic benefits
and risks of the subsequent changes in fair value of the granted shares accordingly to the agreed vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002502"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002504"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002506">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of share-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;General and administrative
        expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002510"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002512"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002516"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002518"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <cik0002065779:SharesDescription
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact002520">0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.</cik0002065779:SharesDescription>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002522"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002524"
      unitRef="Ratio">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002526"
      unitRef="Ratio">0.136</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002528"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002530"
      unitRef="USD">52266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002532"
      unitRef="Ratio">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002534"
      unitRef="Ratio">0.149</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002536"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002541"
      unitRef="Ratio">0.0381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002543"
      unitRef="Ratio">0.155</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002545"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002547"
      unitRef="USD">21104</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002549">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZF2x5NNJfbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;12. &lt;span id="xdx_82E_zervGI5CRFMj"&gt;Related party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Hoansoo Lee serves as the Company&#x2019;s Chief Executive
Officer and Chief Financial Officer. The Company has entered into a consulting services agreement with Hoansoo Lee, pursuant to which
Hoansoo Lee provides strategic consulting and advisory services to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended June&#160;30, 2024 and 2025, the
Company incurred and paid consulting fees totaling $&lt;span id="xdx_902_ecustom--ConsultingFees_c20230701__20240630_pp0p" title="Consulting fees"&gt;75,245&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ConsultingFees_c20240701__20250630_pp0p" title="Consulting fees"&gt;100,150&lt;/span&gt;, respectively. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zv4U4ppRoKV9" title="Outstanding balances payable"&gt;&lt;span id="xdx_906_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20240630_zJHMH77lauR4" title="Outstanding balances payable"&gt;no&lt;/span&gt;&lt;/span&gt;
outstanding balances payable to Hoansoo Lee as all amounts had been fully settled during the respective periods.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cik0002065779:ConsultingFees
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002551"
      unitRef="USD">75245</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002553"
      unitRef="USD">100150</cik0002065779:ConsultingFees>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002555"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002557"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002559">&lt;p id="xdx_80E_eus-gaap--EarningsPerShareTextBlock_zcKacb4NfAse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;13. &lt;span id="xdx_828_zmptkHzMOqij"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share and diluted loss per share have
been calculated in accordance with ASC 260, &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; on computation of loss per share for the years ended
June&#160;30, 2024 and 2025 as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to ordinary
        shareholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator for basic and diluted loss per
        share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted-average ordinary shares outstanding,
        Basic and diluted*&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share"&gt;(3,304.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share"&gt;(5,106.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify"&gt;The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zykAwSGmR6Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002561">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to ordinary
        shareholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator for basic and diluted loss per
        share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted-average ordinary shares outstanding,
        Basic and diluted*&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share"&gt;(3,304.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share"&gt;(5,106.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify"&gt;The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002563"
      unitRef="USD">-4956347</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002564"
      unitRef="USD">-7659667</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002569"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002571"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002573"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002575"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002577"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002579"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002581"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002583"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002587">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zw6BQqHEgLZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;14. &lt;span id="xdx_821_z4EX1JG2ykx6"&gt;Segment information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company manages its business in a centralized
manner and operates as a single segment and accordingly has only one operating and reportable segment, the provision of GPU computing
platform services. The Company&#x2019;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The
CODM regularly reviews entity-level operating results, including revenue and net loss as presented in the statement of operations and
comprehensive loss, when making decisions about resource allocation and assessing segment performance. Therefore, the Company has one
reportable segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary measures of segment revenue and profitability
for the Company&#x2019;s operating segment&#160;are considered to be&#160;revenue and net loss. The CODM uses revenue to assess market
performance and growth, and net loss to evaluate profitability and cost management. Both measures are used together to allocate resources,
including personnel and capital resources. Significant expense categories regularly provided to and reviewed by the CODM include those
presented in the statements of operations and comprehensive loss as well as disaggregated expenses of staff costs and employee benefits,
professional service expenses, share-based compensation, and other general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the segment information
of the Company for the measurement of segment profitability for the years ended June&#160;30, 2024 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;Schedule
    of segment information&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,319,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,015,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cost of revenues&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,263,548&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,910,315&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,365,433&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,797,906&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(262,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(835,889&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2606"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(244,651&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(328,662&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Professional service expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(34,320&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,104&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        from operations&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,845,829&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,044,846&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Change in fair value
        of simple agreements for future equity&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,110,518&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,614,821&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        before income tax expenses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net
        loss&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMAAq6XghBbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Geographic Information&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As substantially all of the Company&#x2019;s long-lived
assets are located in the United States, no geographical segments of assets are presented. The following table presents the Company&#x2019;s
revenue from major geographical areas for the periods indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;260,941&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;2,484,905&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United States of America&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;169,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;2,085,579&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;574,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,443,306&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;157,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;600,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;145,410&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;391,722&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;11,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zSK0DbrUr1O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002589">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;Schedule
    of segment information&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,319,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,015,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cost of revenues&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,263,548&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,910,315&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,365,433&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,797,906&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(262,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(835,889&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2606"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(244,651&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(328,662&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Professional service expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(34,320&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,104&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        from operations&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,845,829&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,044,846&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Change in fair value
        of simple agreements for future equity&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,110,518&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,614,821&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        before income tax expenses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net
        loss&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002591"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002592"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002594"
      unitRef="USD">-1263548</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002595"
      unitRef="USD">-5910315</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002597"
      unitRef="USD">1365433</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002598"
      unitRef="USD">2797906</us-gaap:ResearchAndDevelopmentExpense>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002603"
      unitRef="USD">-262614</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002604"
      unitRef="USD">-835889</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002607"
      unitRef="USD">-153266</cik0002065779:ShareBasedCompensations>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002612"
      unitRef="USD">-244651</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002613"
      unitRef="USD">-328662</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002615"
      unitRef="USD">7594</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002616"
      unitRef="USD">34320</us-gaap:ProfessionalAndContractServicesExpense>
    <cik0002065779:ShareBasedCompensation1
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002618"
      unitRef="USD">21104</cik0002065779:ShareBasedCompensation1>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002621"
      unitRef="USD">-1845829</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002622"
      unitRef="USD">-3044846</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002624"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002625"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002627"
      unitRef="USD">-4956347</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002628"
      unitRef="USD">-7659667</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002633"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002634"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002636">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;260,941&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;2,484,905&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United States of America&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;169,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;2,085,579&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;574,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,443,306&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;157,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;600,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;145,410&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;391,722&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;11,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002638"
      unitRef="USD">260941</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002640"
      unitRef="USD">2484905</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002642"
      unitRef="USD">169600</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002644"
      unitRef="USD">2085579</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002646"
      unitRef="USD">574664</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002648"
      unitRef="USD">1443306</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002650"
      unitRef="USD">157500</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002652"
      unitRef="USD">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002654"
      unitRef="USD">145410</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002656"
      unitRef="USD">391722</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002658"
      unitRef="USD">11000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002660"
      unitRef="USD">10000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002662"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002664"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002667">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zV94gEMyYrl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;15. &lt;span id="xdx_822_zL1TK7zRpema"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From inception to date, the Company has not been a
party to any legal proceedings, claims, or disputes arising in the ordinary course of business. As of June&#160;30, 2025, the Company
had no outstanding litigation, and there were no commitments or contingencies that management believes would have a material effect on
the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002669">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zFgRhy6z3nKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;16. &lt;span&gt;Subsequent events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_829_zHJhA3sZiti7" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated all events and transactions
that occurred after June&#160;30, 2025, up through February&#160;11, 2026, which is the date that these financial statements are issued,
unless as disclosed elsewhere and below, there was no other material subsequent events occurred that would require recognition or disclosure
in the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Incorporation of a Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December&#160;16, 2025, subsequent to the reporting
period but prior to the authorization of these financial statements for issue, the Company incorporated its wholly-owned subsidiary, Evana
Alpha Pte. Ltd., in Singapore. The Company subscribed for all &lt;span id="xdx_90A_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Ordinary shares issued"&gt;1,000&lt;/span&gt; ordinary shares of the subsidiary, with a issued share capital of
Singapore Dollars &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Number of shares issued"&gt;1,000&lt;/span&gt;. The subsidiary&#x2019;s principal business activity is information technology consultancy (excluding cybersecurity).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;SAFEs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From October&#160;1, 2025 to &lt;span style="color: #0F1115; color: #0F1115"&gt;February&#160;11,&lt;/span&gt;
2026, certain institutional and accredited investors provided $&lt;span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_dm_c20251001__20260211__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zobhxoREKnUk" title="Proceeds from safes"&gt;0.5&lt;/span&gt;&#160;million to the Company in the form of SAFEs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Capital Structure and Dual-Class Share Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s
equity is divided into Class A Ordinary Shares and Class B Ordinary Shares, which are entitled to one (1) vote and twenty (20) votes per
share, respectively. Despite the differential in voting power, Class A and Class B Ordinary Shares rank pari passu in all other respects,
sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding warrants, options, and SAFEs are designated
to convert or settle exclusively into Class A Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Business combination agreement and related events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company entered into an
BCA with BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR and D. Boral Arc
Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction, the combined company
will be named Exascale Labs Holdings Inc. and is expected to be traded on a national securities exchange. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate consideration for the Business Combination
is $&lt;span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_dm_c20260101__20260131_z970NdDaFbca" title="Business combination payable"&gt;500.0&lt;/span&gt; million, payable by the surviving publicly traded entity in the form of &lt;span id="xdx_90F_ecustom--OrdinarySharesIssued_c20260101__20260131_pd" title="Ordinary shares issued"&gt;50,000,000&lt;/span&gt; newly issued ordinary shares valued at $&lt;span id="xdx_90D_ecustom--OrdinarySharesPerShare_c20260101__20260131_pd" title="ordinary shares per share"&gt;10.00
&lt;/span&gt;per share. At the effective time of the merger of the Company into the surviving publicly traded entity pursuant to the BCA, the Company&#x2019;s
outstanding ordinary shares and outstanding SAFEs are expected to be cancelled and converted into the right to receive shares of the surviving
publicly traded entity in accordance with the terms of the BCA and the applicable SAFE instruments. Class A ordinary shares are expected
to have one vote per share, and Class B ordinary shares are expected to have 20 votes per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of February&#160;11, 2026, the transactions contemplated
by the BCA had not been consummated. Accordingly, the Company has not recorded any amounts in these financial statements related to the
BCA, as it represents a non-recognized subsequent event.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002671"
      unitRef="Shares">1000</cik0002065779:OrdinarySharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002673"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002675"
      unitRef="USD">500000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002677"
      unitRef="USD">500000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002679"
      unitRef="Shares">50000000</cik0002065779:OrdinarySharesIssued>
    <cik0002065779:OrdinarySharesPerShare
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002681"
      unitRef="USDPShares">10.00</cik0002065779:OrdinarySharesPerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002689"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002690"
      unitRef="USD">984830</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cik0002065779:U.s.DollarCoin
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002693"
      unitRef="USD">4074415</cik0002065779:U.s.DollarCoin>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002695"
      unitRef="USD">152536</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002696"
      unitRef="USD">1830105</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cik0002065779:PrepaidResearchAndDevelopmentExpenses
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002699"
      unitRef="USD">625000</cik0002065779:PrepaidResearchAndDevelopmentExpenses>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002701"
      unitRef="USD">1030761</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002702"
      unitRef="USD">106801</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002704"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002705"
      unitRef="USD">510000</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002707"
      unitRef="USD">1207626</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002710"
      unitRef="USD">7303737</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002711"
      unitRef="USD">8131151</us-gaap:AssetsCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002716"
      unitRef="USD">-0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002717"
      unitRef="USD">95000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002719"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002720"
      unitRef="USD">14406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002722"
      unitRef="USD">19600</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002723"
      unitRef="USD">109406</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002725"
      unitRef="USD">7323337</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002726"
      unitRef="USD">8240557</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002734"
      unitRef="USD">90015</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002735"
      unitRef="USD">743742</us-gaap:AccountsPayableCurrent>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002737"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002738"
      unitRef="USD">26842205</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002740"
      unitRef="USD">432760</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002741"
      unitRef="USD">109657</us-gaap:DepositContractsLiabilities>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002743"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002744"
      unitRef="USD">1174702</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002746"
      unitRef="USD">107481</cik0002065779:OtherCurrentLiabilities>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002747"
      unitRef="USD">283612</cik0002065779:OtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002749"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002750"
      unitRef="USD">29153918</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002752"
      unitRef="USD">20319721</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002753"
      unitRef="USD">29153918</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002764"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002766"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002768"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002770"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002761"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002772"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002774"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002776"
      unitRef="Shares">303</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002778"
      unitRef="Shares">303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002782"
      unitRef="USD">3</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002784"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002786"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002788"
      unitRef="Shares">1197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002790"
      unitRef="Shares">1197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002794"
      unitRef="USD">12</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002796"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002797"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002799"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002800"
      unitRef="USD">-21134012</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002802"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002803"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002805"
      unitRef="USD">7323337</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002806"
      unitRef="USD">8240557</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002808"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002809"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002810"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002811"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002813"
      unitRef="USD">-1649077</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002814"
      unitRef="USD">-3167659</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002815"
      unitRef="USD">-3827444</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002816"
      unitRef="USD">-8902966</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002818"
      unitRef="USD">213081</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002819"
      unitRef="USD">586927</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002820"
      unitRef="USD">648441</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002821"
      unitRef="USD">1658365</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002828"
      unitRef="USD">378511</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002829"
      unitRef="USD">104729</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002830"
      unitRef="USD">726914</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002831"
      unitRef="USD">310582</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002833"
      unitRef="USD">103107</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002834"
      unitRef="USD">468696</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002835"
      unitRef="USD">268159</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002836"
      unitRef="USD">928255</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002838"
      unitRef="USD">377999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002839"
      unitRef="USD">1235476</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002840"
      unitRef="USD">2115853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002841"
      unitRef="USD">3238185</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002843"
      unitRef="USD">859617</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002844"
      unitRef="USD">1808901</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002845"
      unitRef="USD">3110926</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002846"
      unitRef="USD">4477022</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002848"
      unitRef="USD">-646536</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002849"
      unitRef="USD">-1221974</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002850"
      unitRef="USD">-2462485</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002851"
      unitRef="USD">-2818657</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002853"
      unitRef="USD">890523</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002854"
      unitRef="USD">1410457</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002855"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002856"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002858"
      unitRef="USD">-1537059</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002859"
      unitRef="USD">-2632431</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002860"
      unitRef="USD">-6178537</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002861"
      unitRef="USD">-7916977</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002868"
      unitRef="USD">-1537059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002869"
      unitRef="USD">-2632431</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002870"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002871"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002878"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002880"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002882"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002884"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002886"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002888"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002890"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002892"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002894"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002896"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002898"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002899"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002901"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002902"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002904"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002905"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002912"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002907"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002908"
      unitRef="USD">119636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002909"
      unitRef="USD">-10198846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002910"
      unitRef="USD">-10079195</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002916"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002917"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002920"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002922"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002929"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002924"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002925"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002926"
      unitRef="USD">-11735905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002927"
      unitRef="USD">-11515254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002936"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002931"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002932"
      unitRef="USD">67370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002933"
      unitRef="USD">-5557368</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002934"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002940"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002941"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002944"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002946"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002953"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002948"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002949"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002950"
      unitRef="USD">-11735905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002951"
      unitRef="USD">-11515254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002962"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002955"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002958"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002959"
      unitRef="USD">-18501581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002960"
      unitRef="USD">-18280930</us-gaap:StockholdersEquity>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002975"
      unitRef="Shares">-1500</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002968"
      unitRef="USD">-15</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002977"
      unitRef="Shares">303</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002969"
      unitRef="USD">3</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002979"
      unitRef="Shares">1197</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002970"
      unitRef="USD">12</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002985"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002986"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002997"
      unitRef="Shares">303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002989"
      unitRef="USD">3</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002999"
      unitRef="Shares">1197</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002990"
      unitRef="USD">12</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002991"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002992"
      unitRef="USD">-21134012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002993"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003008"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003001"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003004"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003005"
      unitRef="USD">-13217035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003006"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003021"
      unitRef="Shares">-1500</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003014"
      unitRef="USD">-15</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003023"
      unitRef="Shares">303</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003015"
      unitRef="USD">3</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003025"
      unitRef="Shares">1197</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003016"
      unitRef="USD">12</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003031"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003032"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003043"
      unitRef="Shares">303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003035"
      unitRef="USD">3</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003045"
      unitRef="Shares">1197</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003036"
      unitRef="USD">12</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003037"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003038"
      unitRef="USD">-21134012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003039"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003050"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003051"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003056"
      unitRef="USD">4633</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003057"
      unitRef="USD">5194</us-gaap:Depreciation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003059"
      unitRef="USD">153266</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003062"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003063"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003066"
      unitRef="USD">1681167</cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003071"
      unitRef="USD">10483</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003072"
      unitRef="USD">1677569</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003074"
      unitRef="USD">278612</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003075"
      unitRef="USD">-923960</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003078"
      unitRef="USD">625000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003080"
      unitRef="USD">-104717</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003081"
      unitRef="USD">653727</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003083"
      unitRef="USD">-113693</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003084"
      unitRef="USD">176131</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003086"
      unitRef="USD">144082</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003087"
      unitRef="USD">-323103</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003089"
      unitRef="USD">150000</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003090"
      unitRef="USD">-171125</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003092"
      unitRef="USD">224279</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003093"
      unitRef="USD">-270878</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003095"
      unitRef="USD">-1835770</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003096"
      unitRef="USD">-1707626</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003098"
      unitRef="USD">-757960</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003099"
      unitRef="USD">-3758611</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003105"
      unitRef="USD">606752</cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003107"
      unitRef="USD">2138</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003110"
      unitRef="USD">-2138</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003111"
      unitRef="USD">606752</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cik0002065779:PaymentForDeferredOfferingCosts
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003117"
      unitRef="USD">95000</cik0002065779:PaymentForDeferredOfferingCosts>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003119"
      unitRef="USD">4275000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003122"
      unitRef="USD">4275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003123"
      unitRef="USD">-95000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003125"
      unitRef="USD">3514902</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003126"
      unitRef="USD">-3246859</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003128"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003129"
      unitRef="USD">4231689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003131"
      unitRef="USD">4484528</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003132"
      unitRef="USD">984830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesAssumed1
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003144"
      unitRef="USD">500000</us-gaap:NotesAssumed1>
    <us-gaap:LoansAssumed1
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003147"
      unitRef="USD">3000000</us-gaap:LoansAssumed1>
    <us-gaap:NatureOfOperations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003149">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zZfsaWCqvzt2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;1.
&lt;span id="xdx_827_zX0y8kzKCG"&gt;Organization and principal activities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
June&#160;1, 2022, Exascale Labs Inc. (the &#x201c;Company&#x201d;) was formally incorporated in the State of Delaware. In accordance with
the Company&#x2019;s Certificate of Incorporation, the total authorized share capital of the Company consists of &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20260331_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; shares of ordinary
shares, with a par value of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share, all of which are of one class. The governance structure of the Company stipulates that the
business and affairs of the Company shall be managed by or under the direction of its board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;16, 2025, the Company incorporated its wholly-owned subsidiary, Evana Alpha Pte. Ltd., in Singapore. The Company subscribed
for all &lt;span id="xdx_907_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zM1cMUnQc5T6" title="Ordinary shares issued"&gt;1,000&lt;/span&gt; ordinary shares of the subsidiary, with a total issued share capital of Singapore Dollars &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zTUt0Dx8cvJd" title="Number of shares issued"&gt;1,000&lt;/span&gt;. The subsidiary&#x2019;s
principal business activity is information technology consultancy (excluding cybersecurity).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is a next-generation artificial intelligence (&#x201c;AI&#x201d;) infrastructure provider operating an asset-light, software-defined
graphics processing unit (&#x201c;GPU&#x201d;) compute platform and related AI infrastructure solutions. Exascale&#x2019;s core business
includes GPU as a Service (&#x201c;GaaS&#x201d;), through which it provides reserved and on-demand access to high-performance GPU compute
capacity sourced from third-party data centers globally, as well as GPU cluster management and optimization services for artificial intelligence
data center (&#x201c;AIDC&#x201d;) operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling,
high-voltage direct current (&#x201c;HVDC&#x201d;) power and energy storage solutions that are designed to address deployment bottlenecks
in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities have not yet generated
revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads, including large
language model (&#x201c;LLM&#x201d;) training, fine-tuning, and high-concurrency inference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2026, the Company adopted an Amended and Restated Certificate of Incorporation, which established a dual-class ordinary share
structure. Under this new structure, the Company&#x2019;s equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary
shares, which are entitled to one (1) vote and twenty (20) votes per share, respectively. Despite the differential in voting power, Class
A and Class B ordinary shares rank pari passu in all other respects, sharing ratably in dividends and any distributions upon liquidation.
Furthermore, all outstanding Simple Agreements for Future Equity (&#x201c;SAFEs&#x201d;) are designated to convert or settle exclusively
into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2026, the Company entered into an Agreement and Plan of Merger (&#x201c;BCA&#x201d;) with D. Boral ARC Acquisition I Corp.(&#x201c;BCAR&#x201d;),
a publicly traded special purpose acquisition company (&#x201c;SPAC&#x201d;), D. Boral ARC Merger Corporation, a Delaware corporation and
a direct, wholly owned subsidiary of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary
of BCAR. Upon closing of the transaction, the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#x201c;PubCo&#x201d;)
and is expected to be traded on a national securities exchange.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003151"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003153"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003155"
      unitRef="Shares">1000</cik0002065779:OrdinarySharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003157"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003159">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3uJvVhT76yk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2.
&lt;span id="xdx_823_zJDfylZ6eVGa"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;a.
&lt;span id="xdx_867_zT6r15wrPfT"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#x201c;USDC&#x201d;) of $&lt;span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin"&gt;5.1 &lt;/span&gt;million
and current liabilities of $29.2 &lt;span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities"&gt;29,153,918&lt;/span&gt;
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 &lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities"&gt;(757,960)&lt;/span&gt;
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 &lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities"&gt;(3,758,611)&lt;/span&gt;
million. The Company incurred net losses of $6.2 &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses"&gt;(6,178,537)&lt;/span&gt;
million and $7.9 &lt;span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses"&gt;(7,916,977)&lt;/span&gt;
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 &lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit"&gt;(21,134,012)&lt;/span&gt;
million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection
with the Company&#x2019;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
purposes of this disclosure, &#x201c;SPAC&#x201d; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#x2019;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#x2019;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;b.
&lt;span id="xdx_860_z2ZzsSnntEpd"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;c.
&lt;span id="xdx_869_zJzlNRZuupR8"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;d.
&lt;span id="xdx_861_zefs2YE20oYg"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
accordance with FASB ASC 820&#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;e.
&lt;span id="xdx_86D_zpLd8Tfyfj3f"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#x201c;US$&#x201d;).
The functional currency of the Company and its subsidiary is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All
transactions are measured and recorded in the Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;f.
&lt;span id="xdx_867_zTk17b0iUrZg"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"&gt;&lt;span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;g.
&lt;span id="xdx_862_zW5hKqqXdcS6"&gt;Crypto assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#x201c;USDT&#x201d;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#x2019;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#x2019;s crypto assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Crypto
assets other than USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets"&gt;644,616&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets"&gt;796,781&lt;/span&gt;.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets"&gt;939,397&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets"&gt;939,397&lt;/span&gt;,
respectively, which resulted in an ending balance of nil. The Company&#x2019;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. &lt;span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"&gt;&lt;span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets"&gt;No&lt;/span&gt;&lt;/span&gt; fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;h.
&lt;span id="xdx_863_z4jvYtW2zBHk"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company adopted Financial Standards Accounting Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial
Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;i.
&lt;span id="xdx_866_zIRNVy8x1Vb6"&gt;Deferred offering costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#x2019; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil &lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs"&gt;95,000&lt;/span&gt; of transaction costs, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;j.
&lt;span id="xdx_866_zzQ6PbxNF5wb"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;k.
&lt;span id="xdx_869_zdl6xUSc9d8g"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;l.
&lt;span id="xdx_866_zznJ5p0oZj1b"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$&lt;span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs"&gt;625,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs"&gt;1,875,000&lt;/span&gt;, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;m.
&lt;span id="xdx_86D_zATAJPzQnQpl"&gt;Other receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#x2019;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables"&gt;1,207,626&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables"&gt;0&lt;/span&gt; nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#x2019;s direction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;n.
&lt;span id="xdx_865_zZTnYmCZy9f7"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;o.
&lt;span id="xdx_86F_zFO7q56sC1Ja"&gt;Refundable deposits payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $&lt;span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable"&gt;1,174,702&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;p.
&lt;span id="xdx_862_zigYXt8xtSLl"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was &lt;span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;q.
&lt;span id="xdx_86C_zSfMxlp0w9ih"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;r.
&lt;span id="xdx_86B_zHHFuv3eFudi"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods
presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019;
credit profiles and service requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(i)
Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous
access to a functioning and secured platform over the contractual term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0px"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Reserved
capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On-demand
(pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(ii)
Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#x2019;s services are performed throughout the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue"&gt;1,862,158&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue"&gt;3,754,586&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue"&gt;4,475,885 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue"&gt;10,561,331&lt;/span&gt; of the revenue of the Company&#x2019;s
was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;s.
&lt;span id="xdx_869_z3dd7lxTNbH4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#x201c;Contract liabilities&#x201d;.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $&lt;span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized"&gt;366,075&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;t.
&lt;span id="xdx_863_z6GbgvPwOLFd"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;u.
&lt;span id="xdx_864_ziTHMzLNeaI4"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses"&gt;76,090&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses"&gt;32,113&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;v.
&lt;span id="xdx_86B_zfPkq0yTYPQi"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;w.
&lt;span id="xdx_866_zkb75BAicCy2"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;x.
&lt;span id="xdx_863_znTdepZ9jHh1"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC Topic 740&#x201d;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;y.
&lt;span id="xdx_865_zxrlWlb60CN6"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value"&gt;0.01&lt;/span&gt; par value each. As of June&#160;30, 2025, there were &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt; shares issued
and outstanding.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated
to &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, there were &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;z.
&lt;span id="xdx_86B_z63uLSARL1W8"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued
and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Employees&#x2019;
share-based awards and non-employees&#x2019; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;aa.
&lt;span id="xdx_864_zR4H5vg2NKs8"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
280, &#x201c;Segment Reporting&#x201d;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#x2019;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#x2019;s business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses the &#x201c;management approach&#x201d; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) for making operating
decisions and assessing performance as the source for determining the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#x2019;s performance
and results of operations on a consolidated basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;bb.
&lt;span id="xdx_86A_zzhxddzLg2h3"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;cc.
&lt;span id="xdx_86C_znQfJNLN3lgc"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;dd.
&lt;span id="xdx_869_zTML0LCjGgK"&gt;Loss per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ee.
&lt;span id="xdx_860_zcInrRKO5aA2"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Dividends
are recognized when declared. &lt;span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"&gt;&lt;span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ff&lt;/i&gt;&lt;/b&gt;.
&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwrHCIubN67h"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company intends to operate as an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#x2019;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;gg.
&lt;span id="xdx_86D_zcwKuWVskW29"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
June&#160;2016, the FASB issued ASU&#160;2016-13, &lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses &lt;/i&gt;(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;). The new accounting standard introduced the current expected
credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#x2019;s statements of income, or statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#x201c;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#x201d;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#x201c;CODM&#x201d;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;hh.
&lt;span id="xdx_86A_z38IxEch0007"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
March&#160;2024, the FASB issued ASU No. 2024-02, &lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt;
(&#x201c;ASU 2024-02&#x201d;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2024, the FASB issued ASU 2024-03 &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this
update intend to improve the disclosures about a public business entity&#x2019;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive
(loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
September&#160;2025, the FASB issued&#160;&lt;i&gt;ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;&lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December&#160;2025,
the FASB issued &lt;i&gt;ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#x2019;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cik0002065779:GoingConcernPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003161">&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;a.
&lt;span id="xdx_867_zT6r15wrPfT"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#x201c;USDC&#x201d;) of $&lt;span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin"&gt;5.1 &lt;/span&gt;million
and current liabilities of $29.2 &lt;span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities"&gt;29,153,918&lt;/span&gt;
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 &lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities"&gt;(757,960)&lt;/span&gt;
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 &lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities"&gt;(3,758,611)&lt;/span&gt;
million. The Company incurred net losses of $6.2 &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses"&gt;(6,178,537)&lt;/span&gt;
million and $7.9 &lt;span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses"&gt;(7,916,977)&lt;/span&gt;
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 &lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit"&gt;(21,134,012)&lt;/span&gt;
million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection
with the Company&#x2019;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
purposes of this disclosure, &#x201c;SPAC&#x201d; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#x2019;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#x2019;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:GoingConcernPolicyTextBlock>
    <cik0002065779:CashAndCashEquivalentsAndU.s.DollarCoin
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003163"
      unitRef="USD">5100000</cik0002065779:CashAndCashEquivalentsAndU.s.DollarCoin>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003165"
      unitRef="USD">29153918</us-gaap:LiabilitiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003167"
      unitRef="USD">-757960</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003169"
      unitRef="USD">-3758611</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003171"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003173"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003175"
      unitRef="USD">-21134012</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003182">&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;b.
&lt;span id="xdx_860_z2ZzsSnntEpd"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003187">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;c.
&lt;span id="xdx_869_zJzlNRZuupR8"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003189">&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;d.
&lt;span id="xdx_861_zefs2YE20oYg"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
accordance with FASB ASC 820&#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <cik0002065779:FunctionalCurrencyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003191">&lt;p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;e.
&lt;span id="xdx_86D_zpLd8Tfyfj3f"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#x201c;US$&#x201d;).
The functional currency of the Company and its subsidiary is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All
transactions are measured and recorded in the Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003193">&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;f.
&lt;span id="xdx_867_zTk17b0iUrZg"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"&gt;&lt;span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003195"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003197"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CryptoAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003202">&lt;p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;g.
&lt;span id="xdx_862_zW5hKqqXdcS6"&gt;Crypto assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#x201c;USDT&#x201d;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#x2019;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#x2019;s crypto assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Crypto
assets other than USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets"&gt;644,616&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets"&gt;796,781&lt;/span&gt;.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets"&gt;939,397&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets"&gt;939,397&lt;/span&gt;,
respectively, which resulted in an ending balance of nil. The Company&#x2019;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. &lt;span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"&gt;&lt;span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets"&gt;No&lt;/span&gt;&lt;/span&gt; fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CryptoAssets>
    <cik0002065779:ReceiptOfDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003204"
      unitRef="USD">644616</cik0002065779:ReceiptOfDigitalAssets>
    <cik0002065779:DisbursementOfDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003206"
      unitRef="USD">796781</cik0002065779:DisbursementOfDigitalAssets>
    <cik0002065779:ReceiptOfDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003208"
      unitRef="USD">939397</cik0002065779:ReceiptOfDigitalAssets>
    <cik0002065779:DisbursementOfDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003210"
      unitRef="USD">939397</cik0002065779:DisbursementOfDigitalAssets>
    <cik0002065779:FairValueGainOrLossOnDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003212"
      unitRef="USD">0</cik0002065779:FairValueGainOrLossOnDigitalAssets>
    <cik0002065779:FairValueGainOrLossOnDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003214"
      unitRef="USD">0</cik0002065779:FairValueGainOrLossOnDigitalAssets>
    <cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003216">&lt;p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;h.
&lt;span id="xdx_863_z4jvYtW2zBHk"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company adopted Financial Standards Accounting Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial
Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock>
    <cik0002065779:DeferredOfferingCostsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003223">&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;i.
&lt;span id="xdx_866_zIRNVy8x1Vb6"&gt;Deferred offering costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#x2019; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil &lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs"&gt;95,000&lt;/span&gt; of transaction costs, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003225"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003227"
      unitRef="USD">95000</us-gaap:DeferredOfferingCosts>
    <cik0002065779:AdvanceToSuppliersPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003229">&lt;p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;j.
&lt;span id="xdx_866_zzQ6PbxNF5wb"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:AdvanceToSuppliersPolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003231">&lt;p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;k.
&lt;span id="xdx_869_zdl6xUSc9d8g"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsReceivablePolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003233"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003235"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <cik0002065779:PrepaidResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003237">&lt;p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;l.
&lt;span id="xdx_866_zznJ5p0oZj1b"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$&lt;span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs"&gt;625,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs"&gt;1,875,000&lt;/span&gt;, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:PrepaidResearchAndDevelopmentExpensesPolicyTextBlock>
    <cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003239"
      unitRef="USD">625000</cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts>
    <cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003241"
      unitRef="USD">1875000</cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts>
    <cik0002065779:OtherReceivablesPolicyRextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003246">&lt;p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;m.
&lt;span id="xdx_86D_zATAJPzQnQpl"&gt;Other receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#x2019;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables"&gt;1,207,626&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables"&gt;0&lt;/span&gt; nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#x2019;s direction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OtherReceivablesPolicyRextBlock>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003248"
      unitRef="USD">1207626</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003250"
      unitRef="USD">0</us-gaap:OtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003252">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;n.
&lt;span id="xdx_865_zZTnYmCZy9f7"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cik0002065779:RefundableDepositsPayablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003254">&lt;p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;o.
&lt;span id="xdx_86F_zFO7q56sC1Ja"&gt;Refundable deposits payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $&lt;span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable"&gt;1,174,702&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsPayablePolicyTextBlock>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003256"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003258"
      unitRef="USD">1174702</cik0002065779:RefundableDepositsPayable>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003260">&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;p.
&lt;span id="xdx_862_zigYXt8xtSLl"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was &lt;span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003262"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003264"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003266">&lt;p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;q.
&lt;span id="xdx_86C_zSfMxlp0w9ih"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003268">&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;r.
&lt;span id="xdx_86B_zHHFuv3eFudi"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods
presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019;
credit profiles and service requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(i)
Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous
access to a functioning and secured platform over the contractual term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0px"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Reserved
capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On-demand
(pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(ii)
Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#x2019;s services are performed throughout the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue"&gt;1,862,158&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue"&gt;3,754,586&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue"&gt;4,475,885 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue"&gt;10,561,331&lt;/span&gt; of the revenue of the Company&#x2019;s
was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDeferredRevenue>
    <cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003275">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003277"
      unitRef="USD">1758921</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003279"
      unitRef="USD">3725315</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003281"
      unitRef="USD">4161985</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003283"
      unitRef="USD">10428983</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003285"
      unitRef="USD">5436</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003287"
      unitRef="USD">1341</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003289"
      unitRef="USD">6482</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003291"
      unitRef="USD">12526</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003293"
      unitRef="USD">1764357</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003295"
      unitRef="USD">3726656</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003297"
      unitRef="USD">4168467</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003299"
      unitRef="USD">10441509</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003304"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003306"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003308"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003310"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003312">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003314"
      unitRef="USD">1764357</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003316"
      unitRef="USD">3726656</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003318"
      unitRef="USD">4168467</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003320"
      unitRef="USD">10441509</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003322"
      unitRef="USD">97801</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003324"
      unitRef="USD">27930</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003326"
      unitRef="USD">307418</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003328"
      unitRef="USD">119822</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003330"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003332"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003334"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003336"
      unitRef="USD">10561331</us-gaap:Revenues>
    <cik0002065779:ContractLiabilitiesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003338">&lt;p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;s.
&lt;span id="xdx_869_z3dd7lxTNbH4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#x201c;Contract liabilities&#x201d;.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $&lt;span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized"&gt;366,075&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ContractLiabilitiesPolicyTextBlock>
    <cik0002065779:RevenueRecognized
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003345"
      unitRef="USD">95326</cik0002065779:RevenueRecognized>
    <cik0002065779:RevenueRecognized
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003347"
      unitRef="USD">366075</cik0002065779:RevenueRecognized>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003349">&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;t.
&lt;span id="xdx_863_z6GbgvPwOLFd"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <cik0002065779:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003351">&lt;p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;u.
&lt;span id="xdx_864_ziTHMzLNeaI4"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses"&gt;76,090&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses"&gt;32,113&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SellingAndMarketingExpensesPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003353"
      unitRef="USD">76090</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003355"
      unitRef="USD">32113</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003357">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;v.
&lt;span id="xdx_86B_zfPkq0yTYPQi"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003359">&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;w.
&lt;span id="xdx_866_zkb75BAicCy2"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003361">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;x.
&lt;span id="xdx_863_znTdepZ9jHh1"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC Topic 740&#x201d;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <cik0002065779:CapitalStructurePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003363">&lt;p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;y.
&lt;span id="xdx_865_zxrlWlb60CN6"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value"&gt;0.01&lt;/span&gt; par value each. As of June&#160;30, 2025, there were &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt; shares issued
and outstanding.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated
to &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, there were &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CapitalStructurePolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003365"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003367"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003369"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003371"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003378"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003380"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003382"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003384"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003386"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003388">&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;z.
&lt;span id="xdx_86B_z63uLSARL1W8"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued
and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Employees&#x2019;
share-based awards and non-employees&#x2019; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003390">&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;aa.
&lt;span id="xdx_864_zR4H5vg2NKs8"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
280, &#x201c;Segment Reporting&#x201d;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#x2019;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#x2019;s business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses the &#x201c;management approach&#x201d; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) for making operating
decisions and assessing performance as the source for determining the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#x2019;s performance
and results of operations on a consolidated basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cik0002065779:RelatedPartiesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003395">&lt;p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;bb.
&lt;span id="xdx_86A_zzhxddzLg2h3"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RelatedPartiesPolicyTextBlock>
    <cik0002065779:ComprehensiveLossPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003397">&lt;p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;cc.
&lt;span id="xdx_86C_znQfJNLN3lgc"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ComprehensiveLossPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003399">&lt;p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;dd.
&lt;span id="xdx_869_zTML0LCjGgK"&gt;Loss per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueRecognitionDividends
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003401">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ee.
&lt;span id="xdx_860_zcInrRKO5aA2"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Dividends
are recognized when declared. &lt;span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"&gt;&lt;span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDividends>
    <us-gaap:Dividends
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003403"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003405"
      unitRef="USD">0</us-gaap:Dividends>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003407">&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ff&lt;/i&gt;&lt;/b&gt;.
&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwrHCIubN67h"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company intends to operate as an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#x2019;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003412">&lt;p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;gg.
&lt;span id="xdx_86D_zcwKuWVskW29"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
June&#160;2016, the FASB issued ASU&#160;2016-13, &lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses &lt;/i&gt;(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;). The new accounting standard introduced the current expected
credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#x2019;s statements of income, or statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#x201c;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#x201d;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#x201c;CODM&#x201d;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003414">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;hh.
&lt;span id="xdx_86A_z38IxEch0007"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
March&#160;2024, the FASB issued ASU No. 2024-02, &lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt;
(&#x201c;ASU 2024-02&#x201d;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2024, the FASB issued ASU 2024-03 &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this
update intend to improve the disclosures about a public business entity&#x2019;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive
(loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
September&#160;2025, the FASB issued&#160;&lt;i&gt;ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;&lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December&#160;2025,
the FASB issued &lt;i&gt;ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#x2019;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003422">&lt;p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zS5TxZ8a2Pfc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;3.
&lt;span id="xdx_829_zr7ePs3Ws0Bk"&gt;Concentration and risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of credit risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Financial
instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company performs ongoing credit evaluations of the customers&#x2019; financial condition and maintains an allowance for potential credit
losses. This allowance consists of an amount identified for specific customers and an amount based on overall estimated exposure. Our
overall estimated exposure excludes amounts covered by credit insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s revenue was concentrated among a limited number of customers during the periods presented. The following table summarized
customers with greater than 10% of the total revenue:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3426"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk"&gt;24.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk"&gt;11.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk"&gt;11.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk"&gt;10.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk"&gt;22.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk"&gt;13.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk"&gt;17.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk"&gt;10.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk"&gt;15.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zpwvFHT7lvqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s account receivable was concentrated among a limited number of customers during the periods presented. The following table
summarized customers with greater than 10% of the total account receivable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk"&gt;29.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk"&gt;19.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk"&gt;10.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zdxUw16dlq13" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s purchases was concentrated among a limited number of suppliers during the periods presented. The following table summarized
suppliers with greater than 10% of the total purchase:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk"&gt;13.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk"&gt;26.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk"&gt;14.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk"&gt;30.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk"&gt;21.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk"&gt;32.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk"&gt;33.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk"&gt;24.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk"&gt;24.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk"&gt;13.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk"&gt;11.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk"&gt;45.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk"&gt;47.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zBBE52ciJOOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s account payable was concentrated among a limited number of suppliers during the periods presented. The following table
summarized suppliers with greater than 10% of the total account payable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_z1KfkhgkdJa9" style="display: none"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk"&gt;74.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk"&gt;13.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003424">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3426"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk"&gt;24.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk"&gt;11.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk"&gt;11.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk"&gt;10.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk"&gt;22.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk"&gt;13.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk"&gt;17.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk"&gt;10.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk"&gt;15.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003428"
      unitRef="Ratio">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003432"
      unitRef="Ratio">0.246</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003434"
      unitRef="Ratio">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003436"
      unitRef="Ratio">0.118</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003438"
      unitRef="Ratio">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003440"
      unitRef="Ratio">0.223</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003442"
      unitRef="Ratio">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003446"
      unitRef="Ratio">0.170</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003454"
      unitRef="Ratio">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003462"
      unitRef="Ratio">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003466"
      unitRef="Ratio">0.156</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfAccountsReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003474">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk"&gt;29.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk"&gt;19.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk"&gt;10.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfAccountsReceivableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003476"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003478"
      unitRef="Ratio">0.297</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003480"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003482"
      unitRef="Ratio">0.195</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003484"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003486"
      unitRef="Ratio">0.105</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003488"
      unitRef="Ratio">0.427</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003490"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003492"
      unitRef="Ratio">0.383</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003494"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003496"
      unitRef="Ratio">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003498"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003502">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk"&gt;13.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk"&gt;26.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk"&gt;14.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk"&gt;30.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk"&gt;21.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk"&gt;32.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk"&gt;33.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk"&gt;24.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk"&gt;24.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk"&gt;13.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk"&gt;11.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk"&gt;45.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk"&gt;47.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003504"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003506"
      unitRef="Ratio">0.130</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003508"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003510"
      unitRef="Ratio">0.264</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003512"
      unitRef="Ratio">0.144</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003514"
      unitRef="Ratio">0.302</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003516"
      unitRef="Ratio">0.211</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003518"
      unitRef="Ratio">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003520"
      unitRef="Ratio">0.329</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003522"
      unitRef="Ratio">0.337</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003524"
      unitRef="Ratio">0.240</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003526"
      unitRef="Ratio">0.242</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003528"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003530"
      unitRef="Ratio">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003532"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003534"
      unitRef="Ratio">0.115</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003536"
      unitRef="Ratio">0.455</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003538"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003540"
      unitRef="Ratio">0.476</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003542"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003544">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_z1KfkhgkdJa9" style="display: none"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk"&gt;74.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk"&gt;13.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003546"
      unitRef="Ratio">0.121</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003548"
      unitRef="Ratio">0.740</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003550"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003552"
      unitRef="Ratio">0.126</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093"
      decimals="INF"
      id="Fact003554"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003556"
      unitRef="Ratio">0.134</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109"
      decimals="INF"
      id="Fact003558"
      unitRef="Ratio">0.549</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003560"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003562"
      unitRef="Ratio">0.323</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003564"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003566">&lt;p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zhBirMcj7P27" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;4.
&lt;span id="xdx_827_ze9UXnp1dT7e"&gt;Fair value measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, information about inputs into the fair value measurement of the Company&#x2019;s assets
and liabilities that are measured at fair value on a recurring basis in periods subsequent to their initial recognition is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3572"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3574"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;March&#160;31,
        &lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0A_zChGi8tau4Y2"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_F10_zFPLD0zjBMIf"&gt;The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; color: #0F1115"&gt;&lt;span id="xdx_F00_zI5V4PyahiJg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z2JSmT6vIOn7"&gt;Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zAeVWeK19ZUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003568">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3572"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3574"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;March&#160;31,
        &lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0A_zChGi8tau4Y2"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_F10_zFPLD0zjBMIf"&gt;The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; color: #0F1115"&gt;&lt;span id="xdx_F00_zI5V4PyahiJg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z2JSmT6vIOn7"&gt;Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003570"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003576"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003578"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003584"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003589"
      unitRef="USD">26842205</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003595"
      unitRef="USD">26842205</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003597"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003603"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CryptoAssetTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003607">&lt;p id="xdx_803_eus-gaap--CryptoAssetTextBlock_zi6RMK8i16tg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;5.
&lt;span id="xdx_829_zy7JjRUSo6a6"&gt;Crypto assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses crypto assets like USDT and USDC as medium of exchange for collecting and settling business-related payments and for receiving
investment proceeds. As of June&#160;30, 2025 and March&#160;31, 2026, the Company held nil and 4,074,415 units of USDT and USDC, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the nine months ended March&#160;31, 2026, the movement for digital assets and USDC were as below&#xff1a;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of digital assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Digital assets&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions"&gt;939,397&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions"&gt;4,711,169&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals
        - sold for US dollars&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars"&gt;(596,852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars"&gt;(9,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Disposals - others&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals"&gt;(342,545&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals"&gt;(626,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3627"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance"&gt;4,074,415&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F05_z0wsheXoxiZe"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zlhgBGZ4Kxka"&gt;The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_zMHGNT0qLCIg"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1F_z3QKCOoBgzb2"&gt;The Company used digital assets and USDC to settle professional service
        fees and other expenditures.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zlzUyMcRzUte" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s balances related to digital assets are USD-pegged stablecoins. No fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following table summarizes other operating activities settled in digital assets and USDC:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B8_zB2Vyc1Bo39h"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        ended March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue"&gt;(1,197,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other
        receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets"&gt;(1,452,102&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Cost and
        expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses"&gt;969,399&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Interest
        income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income"&gt;(1,138&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total
        operating activities settled in digital assets and USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC"&gt;(1,681,167&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zJhdLNbXqBJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During
the three and nine months ended March&#160;31, 2026, the Company received $&lt;span id="xdx_90D_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20250701__20260331_zf0QgnFTWzBf" title="Investment proceeds"&gt;&lt;span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20260101__20260331_z5QJhWbmUOj2" title="Investment proceeds"&gt;3.0&lt;/span&gt;&lt;/span&gt; million of investment proceeds from SAFEs in USDC. These
amounts were disclosed as supplemental non-cash financing information and therefore were not included in net cash provided by financing
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CryptoAssetTextBlock>
    <us-gaap:CryptoAssetActivityTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003609">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of digital assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Digital assets&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions"&gt;939,397&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions"&gt;4,711,169&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals
        - sold for US dollars&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars"&gt;(596,852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars"&gt;(9,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Disposals - others&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals"&gt;(342,545&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals"&gt;(626,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3627"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance"&gt;4,074,415&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F05_z0wsheXoxiZe"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zlhgBGZ4Kxka"&gt;The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_zMHGNT0qLCIg"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1F_z3QKCOoBgzb2"&gt;The Company used digital assets and USDC to settle professional service
        fees and other expenditures.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CryptoAssetActivityTableTextBlock>
    <us-gaap:CryptoAssetPurchase
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003615"
      unitRef="USD">939397</us-gaap:CryptoAssetPurchase>
    <us-gaap:CryptoAssetPurchase
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003617"
      unitRef="USD">4711169</us-gaap:CryptoAssetPurchase>
    <us-gaap:CryptoAssetSale
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003619"
      unitRef="USD">596852</us-gaap:CryptoAssetSale>
    <us-gaap:CryptoAssetSale
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003621"
      unitRef="USD">9900</us-gaap:CryptoAssetSale>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003623"
      unitRef="USD">342545</us-gaap:CryptoAssetDisposition>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003625"
      unitRef="USD">626854</us-gaap:CryptoAssetDisposition>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003629"
      unitRef="USD">4074415</us-gaap:CryptoAssetFairValue>
    <us-gaap:CashFlowOperatingCapitalTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003636">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B8_zB2Vyc1Bo39h"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        ended March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue"&gt;(1,197,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other
        receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets"&gt;(1,452,102&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Cost and
        expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses"&gt;969,399&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Interest
        income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income"&gt;(1,138&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total
        operating activities settled in digital assets and USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC"&gt;(1,681,167&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CashFlowOperatingCapitalTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003638"
      unitRef="USD">-1197326</us-gaap:Revenues>
    <cik0002065779:OtherCurrentAssets
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003640"
      unitRef="USD">-1452102</cik0002065779:OtherCurrentAssets>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003642"
      unitRef="USD">969399</us-gaap:CostsAndExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003644"
      unitRef="USD">1138</us-gaap:InterestIncomeOther>
    <cik0002065779:TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003646"
      unitRef="USD">-1681167</cik0002065779:TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003648"
      unitRef="USD">3000000.0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003650"
      unitRef="USD">3000000.0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:AccountsAndNontradeReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003652">&lt;p id="xdx_801_eus-gaap--AccountsAndNontradeReceivableTextBlock_zt83sqIk2p94" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;6.
&lt;span id="xdx_821_zw6NyDc9ffw7"&gt;Accounts receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts
        receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;152,536&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,830,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        allowance for credit losses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Accounts
        receivable, net&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;152,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,830,105&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for credit losses for expected
losses over the life of the accounts receivable using the current expected credit loss methodology. The Company determines the allowance
based on historical loss experience, current conditions, and reasonable and supportable forecasts. As of June&#160;30, 2025 and March&#160;31,
2026, there was &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zYCAUmcH4Uyf" title="Allowance for credit losses"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zI2AqCult1gj" title="Allowance for credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003654">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts
        receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;152,536&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,830,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        allowance for credit losses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Accounts
        receivable, net&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;152,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,830,105&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003656"
      unitRef="USD">152536</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003657"
      unitRef="USD">1830105</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003659"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003660"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003662"
      unitRef="USD">152536</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003663"
      unitRef="USD">1830105</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003665"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003667"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003669">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdX7g6UQPBw2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;7.
&lt;span id="xdx_822_zmlf6pOH23ii"&gt;Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,198&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,944&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,198&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        carrying amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;19,600&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;14,406&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation
expenses for the three months ended March&#160;31, 2025 and 2026 were $&lt;span id="xdx_909_eus-gaap--Depreciation_c20250101__20250331_pp0p" title="Depreciation expenses"&gt;1,601&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_c20260101__20260331_pp0p" title="Depreciation expenses"&gt;1,565&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation
expenses for the nine months ended March&#160;31, 2025 and 2026 were $&lt;span id="xdx_902_eus-gaap--Depreciation_c20240701__20250331_pp0p" title="Depreciation expenses"&gt;4,633&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20250701__20260331_pp0p" title="Depreciation expenses"&gt;5,194&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003671">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,198&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,944&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,198&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        carrying amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;19,600&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;14,406&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003673"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003674"
      unitRef="USD">29198</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003676"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003677"
      unitRef="USD">29198</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003679"
      unitRef="USD">10344</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003680"
      unitRef="USD">14792</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003682"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003683"
      unitRef="USD">14406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003687"
      unitRef="USD">1601</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003689"
      unitRef="USD">1565</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003691"
      unitRef="USD">4633</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003693"
      unitRef="USD">5194</us-gaap:Depreciation>
    <cik0002065779:SimpleAgreementsForFutureEquityTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003695">&lt;p id="xdx_800_ecustom--SimpleAgreementsForFutureEquityTextBlock_zvL0mGPqikAj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;8.
&lt;span id="xdx_826_zuUPRpykS4s9"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company has entered into SAFEs with various investors that were classified as liabilities on the Company&#x2019;s balance sheets and accounted
for at fair value, subject to remeasurement each reporting period. Each SAFEs has no maturity date, does not bear any interest and provides
the investor with the right to convert into a variable number of shares of future equity in the Company at the stated conversion amount,
if certain events or conditions are triggered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During
the period from October&#160;2022 through March&#160;31, 2026, the Company entered into Simple Agreements for Future Equity with third-party
investors, receiving aggregate gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromOtherEquity_c20221001__20260331_pp0p" title="Aggregate gross proceeds"&gt;14,092,500&lt;/span&gt;. For the nine months ended March&#160;31, 2025 and 2026, the Company received
SAFEs proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_pp0d_c20240701__20250331_zUakL51Li8jh" title="Aggregate gross proceeds"&gt;4,275,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ProceedsFromOtherEquity_pp0d_c20250701__20260331_z2WDlnQfzWRe" title="Aggregate gross proceeds"&gt;3,500,000&lt;/span&gt;, respectively, with nil and $3,000,000 received in USDC, respectively. No issuance costs were incurred in connection with these arrangements. As of
the date these unaudited condensed consolidated financial statements are issued, none of the SAFEs have been settled or converted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
SAFEs agreements grant investors the right to participate in the Company&#x2019;s future equity financing events. The agreements contain
various conversion and redemption provisions, including conversion upon an equity financing event, as well as settlement in the event
of a liquidity event or dissolution of the Company. Key terms of the SAFEs are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Equity
Financing&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Upon the occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the
number of shares of preferred stock equal to SAFEs purchase amount divided by the lowest price per share paid for the standard preferred
stock or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;SAFEs price&#x201d; means is calculated by dividing a fixed post-money
        valuation cap by the Company capitalization, a defined term that includes all outstanding equity and convertible instruments.&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Equity Financing&#x201d; means a bona fide transaction or series
        of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells preferred share at a fixed
        valuation, including but not limited to, a pre-money or post-money valuation.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Not
all SAFEs agreements contain the equity financing conversion provision described above. Certain SAFEs are structured without an Equity
Financing conversion feature and are generally settled only upon a Liquidity Event or a Dissolution Event (as defined in the respective
SAFEs agreements). The Company considered the contractual terms of the SAFEs, including whether an Equity Financing conversion feature
is present and the settlement provisions upon a Liquidity Event or a Dissolution Event, in the valuation and measurement of these instruments.
As of March&#160;31, 2026, &lt;span id="xdx_90F_ecustom--EquityFinancingDescription_c20240701__20250331_z5HMRpZeny35" title="Equity Financing description"&gt;SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not have any preferred stock outstanding as of the date these unaudited condensed consolidated financial statements are issued;
therefore, an equity financing event has not been triggered.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"&gt;&lt;b&gt;&lt;i&gt;Liquidity
Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to the greater of (i) SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal
to the purchase amount divided by the Liquidity Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Liquidity Price&#x201d; is calculated by dividing the post-money
        valuation cap by the separately defined capital base, referred to as &#x201c;liquidity capitalization&#x201d; in the SAFEs agreements.&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Liquidity Event&#x201d; means a change of control, a direct Listing
        or an initial public offering.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Dissolution
Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to receive a portion of proceeds equal to SAFEs purchase amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company classifies its SAFEs as financial liabilities measured at fair value. Since the value of these instruments depends on significant
unobservable inputs, including future financing activities and liquidity events, they are classified as Level 3 within the fair value
hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurement utilizes a combined scenario analysis and financial instrument decomposition approach. Based on management&#x2019;s
assessment of the Company&#x2019;s prospects, probability distributions are assigned to potential settlement-triggering events. Valuation
is performed using a &#x201c;debt plus option&#x201d; model: the debt component is valued using a discounted cash flow method with key assumptions
including expected settlement timing, risk-free interest rate, and credit spread; the embedded conversion right is treated as a call option
and valued using the Black-Scholes model, with key inputs including the fair value of ordinary shares, expected term, and volatility.
The overall fair value represents the probability-weighted sum across all scenarios, supported by an independent third-party valuation
specialist.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, the SAFE liabilities were measured at fair value using the above Level 3 methodology. Significant
unobservable inputs&#x2014;including timing of events, volatility, and credit spreads&#x2014;are based on management&#x2019;s reasonable
estimates as of each valuation date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following tables set forth a summary of the activity of the SAFE liabilities, respectively, which represents a recurring fair value measurement
at the end of each reporting period:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity"&gt;4,275,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value"&gt;3,716,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending"&gt;17,312,616&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning"&gt;18,243,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value"&gt;5,098,320&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending"&gt;26,842,205&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Subsequent
to March&#160;31, 2026 (see Note 1), in connection with the proposed business combination, the outstanding SAFEs are expected to be settled
upon the closing of the transaction (the &#x201c;Closing&#x201d;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination
of the SAFEs, each SAFE will automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;At
the Closing of the BCA transaction, each SAFE is expected to convert into Class A shares of PubCo, if the amount payable of $26,842,205
is greater than the purchase amount.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityTextBlock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-10-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003697"
      unitRef="USD">14092500</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003699"
      unitRef="USD">4275000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003701"
      unitRef="USD">3500000</us-gaap:ProceedsFromOtherEquity>
    <cik0002065779:EquityFinancingDescription
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="Fact003703">SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.</cik0002065779:EquityFinancingDescription>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003708">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity"&gt;4,275,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value"&gt;3,716,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending"&gt;17,312,616&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning"&gt;18,243,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value"&gt;5,098,320&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending"&gt;26,842,205&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003710"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003712"
      unitRef="USD">4275000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003714"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003716"
      unitRef="USD">17312616</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003718"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003720"
      unitRef="USD">3500000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003722"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003724"
      unitRef="USD">26842205</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003727">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zyFahVjLxWI4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;9.
&lt;span id="xdx_82B_ziKKVuFGi2S9"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Exascale
Labs Inc. is incorporated in the State of Delaware and is subject to income taxes in its primary jurisdictions: U.S. federal income
tax, California state corporate income tax and Delaware state corporate income tax. The statutory tax rates applicable to the
Company are &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20250701__20260331_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt;
at the federal level, 8.84% at the California state level and &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20250701__20260331_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt;
at the Delaware state level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Evana
Alpha Pte. Ltd. is incorporated in Singapore and is subject to the statutory corporate income tax rate of &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331__us-gaap--IncomeTaxAuthorityNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Effective income tax rate"&gt;17%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
current and deferred components of income tax expense reflected in the statements of operations and comprehensive loss were nil &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331_zQiioohpuxS4" title="Effective income tax rate"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250331_zur6gJAGXbi2" style="display: none" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/span&gt;
for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s effective income tax rate was&#160;nil&#160;for the nine months ended March&#160;31, 2025 and 2026. This was primarily
attributable to the&#160;recognition of a full valuation allowance against the net deferred tax assets, as the Company has concluded that
it is not more likely than not that these assets will be realized in the foreseeable future. Accordingly, no tax benefit has been recognized
for the losses incurred during these periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company
had no unrecognized tax benefits as of March 31, 2026. The Company currently files income tax returns in the United States, as well as
Delaware and California. All tax years are open for examination. The Company currently has no federal or state tax examinations in progress.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003729"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003731"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003733"
      unitRef="Ratio">0.17</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003735"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003737"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003739">&lt;p id="xdx_809_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zmD9QmjKORy7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;10.
&lt;span id="xdx_820_zFODMdXSgusi"&gt;Share-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2025, total share-based compensation expenses recognized were $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250101__20250331_pp0p" title="Share-based compensation expenses"&gt;101,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20240701__20250331_pp0p" title="Share-based compensation expenses"&gt;153,266&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2026, total share-based compensation expenses recognized were nil&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20260101__20260331_pp0p" title="Share-based compensation expenses"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250701__20260331_pp0p" style="display: none" title="Share-based compensation expenses"&gt;0&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(1)
Employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
January&#160;6, 2025, with the approval from the Board of the Company, an employee was granted equity award from inception of the employment
agreement, which represented &lt;span id="xdx_901_ecustom--GrantedEquityAward_c20250106__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Granted equity award"&gt;0.1%&lt;/span&gt; of the Company&#x2019;s total shares outstanding at issuance date (the &#x201c;0.1% Award&#x201d;, i.e.,
1.5 shares). The equity award had a vesting period of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_z1Z0diGK94pe" title="Vesting period"&gt;24&lt;/span&gt; months after grant, but with no requisite service period. Alongside the employee&#x2019;s
separation in September&#160;2025, the equity award remained its vesting pace under the 24-month vesting schedule. As of March&#160;31,
2026, &lt;span id="xdx_906_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_zlx0SpyKOQ08" title="Shares description"&gt;0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(2)
Non-employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;2, 2024, with the approval from the Board of the Company, a contractor was granted equity award from inception of the contractor
agreement representing &lt;span id="xdx_908_ecustom--GrantedEquityAward_c20241202__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Granted equity award"&gt;0.053333%&lt;/span&gt; of the Company&#x2019;s total shares outstanding at issuance date (&#x201c;0.05% Award&#x201d;, i.e., 0.8
shares). The equity award had a vesting period of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_zQkNCDGTocwl" title="Vesting period"&gt;24&lt;/span&gt; months after grant, with half vested as of April&#160;1, 2025 and remaining as of
November&#160;1, 2026, but with no requisite service period. As of March&#160;31, 2026, &lt;span id="xdx_904_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_z3nHrh1RAC13" title="Shares description"&gt;the first half of the equity award had been vested&lt;/span&gt;,
the remaining half had been outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in the issued
and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total
issued and outstanding shares. The vested shares are not recorded in the individual names of the holders on the Company&#x2019;s stock
ledger, but held by the controlling shareholder on their behalf, mainly due to the plan to a direct register of shares under the listed
company during de-SPAC transaction. The Company, as well as the controlling shareholder deemed the grant as the time when the employee
and non-employees are entitled to economic benefits and risks of the subsequent changes in fair value of the granted shares accordingly
to the agreed vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003741"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003743"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003745"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003747"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <cik0002065779:GrantedEquityAward
      contextRef="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003749"
      unitRef="Ratio">0.001</cik0002065779:GrantedEquityAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003751">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cik0002065779:SharesDescription
      contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003753">0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.</cik0002065779:SharesDescription>
    <cik0002065779:GrantedEquityAward
      contextRef="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003755"
      unitRef="Ratio">0.00053333</cik0002065779:GrantedEquityAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003757">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cik0002065779:SharesDescription
      contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003759">the first half of the equity award had been vested</cik0002065779:SharesDescription>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003761">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW0BXdSt3Dza" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;11.
&lt;span id="xdx_826_zRqJaIvukVIi"&gt;Related party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Hoansoo
Lee serves as the Company&#x2019;s Chief Executive Officer and Chief Financial Officer. The Company has entered into a consulting services
agreement with Hoansoo Lee, pursuant to which Hoansoo Lee provides strategic consulting and advisory services to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2025, the Company incurred consulting service fees of $&lt;span id="xdx_90F_ecustom--ConsultingFees_c20250101__20250331_pp0p" title="Consulting fees"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--ConsultingFees_c20240701__20250331_pp0p" title="Consulting fees"&gt;73,150&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2026, the Company incurred consulting service fees of nil &lt;span id="xdx_901_ecustom--ConsultingFees_c20260101__20260331_pp0p" style="display: none" title="Consulting fees"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ConsultingFees_c20250701__20260331_pp0p" title="Consulting fees"&gt;27,000&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, there were &lt;span id="xdx_90A_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zypmsCbXcuw1" title="Outstanding balances payable"&gt;&lt;span id="xdx_90D_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20260331_zGm0xhqAZNP4" title="Outstanding balances payable"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding balances payable to Hoansoo Lee as all amounts had been fully
settled during the respective periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cik0002065779:ConsultingFees
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003763"
      unitRef="USD">27000</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003765"
      unitRef="USD">73150</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003767"
      unitRef="USD">0</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003769"
      unitRef="USD">27000</cik0002065779:ConsultingFees>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003771"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003773"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003775">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_z4GoZXwnHKv4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;12.
&lt;span id="xdx_829_zB59rzSX6LQb"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
loss per share and diluted loss per share have been calculated in accordance with ASC 260, &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; on
computation of earnings per share for the three and nine months ended March&#160;31, 2025 and 2026 as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Numerator:&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Net loss
        attributable to ordinary shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,537,059&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,632,431&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,178,537&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,916,977&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Denominator:&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Denominator
        for basic and diluted loss per share&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Weighted-average
        ordinary shares outstanding&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share"&gt;(1,024.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share"&gt;(1,754.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share"&gt;(4,119.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share"&gt;(5,277.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F08_zYCld0TSLmlc"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zckvTnJmQEhg"&gt;In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F07_zMNm9OVFQe92"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zgBQGgyBG4z3"&gt;During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zRrW0FzXJpr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003777">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Numerator:&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Net loss
        attributable to ordinary shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,537,059&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,632,431&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,178,537&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,916,977&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Denominator:&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Denominator
        for basic and diluted loss per share&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Weighted-average
        ordinary shares outstanding&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share"&gt;(1,024.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share"&gt;(1,754.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share"&gt;(4,119.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share"&gt;(5,277.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F08_zYCld0TSLmlc"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zckvTnJmQEhg"&gt;In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F07_zMNm9OVFQe92"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zgBQGgyBG4z3"&gt;During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003784"
      unitRef="USD">-1537059</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003785"
      unitRef="USD">-2632431</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003786"
      unitRef="USD">-6178537</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003787"
      unitRef="USD">-7916977</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003799"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003801"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003803"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003805"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003807"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003809"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003811"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003813"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003820"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003822"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003824"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003826"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003828"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003830"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003832"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003834"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003838">&lt;p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zEoFgwHUEmak" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;13.
&lt;span id="xdx_82A_zGToUPHTxt3k"&gt;Segment information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company manages its business in a centralized manner and operates as a single segment and accordingly has only one operating and reportable
segment, the provision of GPU computing platform services. The Company&#x2019;s Chief Executive Officer serves as the CODM. The CODM regularly
reviews entity-wide operating results and reviews consolidated revenues and net loss as reported in the statement of operations and comprehensive
loss when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
primary measures of segment revenue and profitability for the Group&#x2019;s operating segment&#160;are considered to be&#160;consolidated&#160;revenue
and net loss.&#160;The CODM uses consolidated revenue to assess market performance and growth, and net loss to evaluate segment profitability
and cost management. Both measures are used together to allocate resources, including employee or capital resources. Significant expense
categories regularly provided to and reviewed by the CODM include those presented in the statements of operations and comprehensive loss
as well as disaggregated expenses of staff costs and employee benefits, professional service expenses, share-based compensation, and other
general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following table presents the segment information of the Company for the measurement of segment profitability for the three and nine months
ended March&#160;31, 2025 and 2026:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of segment information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,862,158&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,754,586&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4,475,885&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10,561,331&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost
        of revenues&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,649,077&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,167,659&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,827,444&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,902,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Gross
        profit&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;213,081&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;586,927&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;648,441&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;1,658,365&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research
        and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(377,999&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,235,476&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,115,853&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,238,185&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Selling
        and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(277,511&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(104,729&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(573,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(310,582&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(101,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3876"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3878"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General
        and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,890&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(360,657&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(33,785&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(563,641&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&#x2013;
        Professional service expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(99,217&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(234,374&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(364,614&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Loss
        from operations&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(646,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(1,221,974&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,462,485&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,818,657&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Change
        in fair value of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(890,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,410,457&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,716,052&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,098,320&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Income
        tax expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3905"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3907"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3908"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        loss&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(1,537,059&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(2,632,431&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(6,178,537&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(7,916,977&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zZ3FKbItpbC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Substantially
all of the Company&#x2019;s long-lived assets are located in the United States. The following table presents the Company&#x2019;s revenue
from major geographical areas for the periods indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        States of America&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;581,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,564,836&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,273,279&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;4,560,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;367,107&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,139,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,089,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;3,232,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Singapore&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;662,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;425,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,361,844&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,237,464&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;417,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;450,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;1,118,534&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;98,483&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;207,694&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;291,203&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;412,015&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;3,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3959"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3963"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z1dwOhMrHlX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003843">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of segment information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,862,158&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,754,586&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4,475,885&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10,561,331&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost
        of revenues&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,649,077&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,167,659&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,827,444&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,902,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Gross
        profit&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;213,081&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;586,927&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;648,441&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;1,658,365&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research
        and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(377,999&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,235,476&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,115,853&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,238,185&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Selling
        and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(277,511&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(104,729&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(573,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(310,582&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(101,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3876"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3878"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General
        and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,890&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(360,657&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(33,785&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(563,641&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&#x2013;
        Professional service expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(99,217&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(234,374&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(364,614&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Loss
        from operations&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(646,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(1,221,974&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,462,485&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,818,657&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Change
        in fair value of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(890,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,410,457&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,716,052&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,098,320&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Income
        tax expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3905"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3907"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3908"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        loss&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(1,537,059&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(2,632,431&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(6,178,537&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(7,916,977&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003845"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003846"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003847"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003848"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003850"
      unitRef="USD">-1649077</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003851"
      unitRef="USD">-3167659</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003852"
      unitRef="USD">-3827444</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003853"
      unitRef="USD">-8902966</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003855"
      unitRef="USD">213081</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003856"
      unitRef="USD">586927</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003857"
      unitRef="USD">648441</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003858"
      unitRef="USD">1658365</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003860"
      unitRef="USD">377999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003861"
      unitRef="USD">1235476</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003862"
      unitRef="USD">2115853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003863"
      unitRef="USD">3238185</us-gaap:ResearchAndDevelopmentExpense>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003870"
      unitRef="USD">-277511</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003871"
      unitRef="USD">-104729</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003872"
      unitRef="USD">-573648</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003873"
      unitRef="USD">-310582</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003875"
      unitRef="USD">-101000</cik0002065779:ShareBasedCompensations>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003877"
      unitRef="USD">-153266</cik0002065779:ShareBasedCompensations>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003885"
      unitRef="USD">-3890</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003886"
      unitRef="USD">-360657</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003887"
      unitRef="USD">-33785</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003888"
      unitRef="USD">-563641</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003890"
      unitRef="USD">99217</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003891"
      unitRef="USD">108039</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003892"
      unitRef="USD">234374</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003893"
      unitRef="USD">364614</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003895"
      unitRef="USD">-646536</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003896"
      unitRef="USD">-1221974</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003897"
      unitRef="USD">-2462485</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003898"
      unitRef="USD">-2818657</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003900"
      unitRef="USD">890523</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003901"
      unitRef="USD">1410457</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003902"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003903"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003910"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003911"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003912"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003913"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003915">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        States of America&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;581,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,564,836&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,273,279&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;4,560,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;367,107&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,139,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,089,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;3,232,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Singapore&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;662,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;425,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,361,844&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,237,464&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;417,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;450,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;1,118,534&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;98,483&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;207,694&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;291,203&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;412,015&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;3,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3959"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3963"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003917"
      unitRef="USD">581009</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003919"
      unitRef="USD">1564836</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003921"
      unitRef="USD">1273279</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003923"
      unitRef="USD">4560992</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003925"
      unitRef="USD">367107</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003927"
      unitRef="USD">1139055</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003929"
      unitRef="USD">1089559</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003931"
      unitRef="USD">3232326</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003933"
      unitRef="USD">662559</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003935"
      unitRef="USD">425009</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003937"
      unitRef="USD">1361844</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003939"
      unitRef="USD">1237464</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003941"
      unitRef="USD">150000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003943"
      unitRef="USD">417992</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003945"
      unitRef="USD">450000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003947"
      unitRef="USD">1118534</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003949"
      unitRef="USD">98483</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003951"
      unitRef="USD">207694</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003953"
      unitRef="USD">291203</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003955"
      unitRef="USD">412015</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003957"
      unitRef="USD">3000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003961"
      unitRef="USD">10000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003965"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003967"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003969"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003971"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003974">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLihNGvAxZLg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;14.
&lt;span id="xdx_827_zx6q22XsxzOc"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;From
inception to date, the Company has not been a party to any legal proceedings, claims, or disputes arising in the ordinary course of business.
As of March&#160;31, 2026, the Company had no outstanding litigation, and there were no commitments or contingencies that management believes
would have a material effect on the unaudited condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003976">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zRLEv2ZbvEdd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;15.
Subsequent events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_82A_zSew4Do77Ac5" style="display: none"&gt;Subsequent Events&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company
evaluated all events and transactions that occurred after March&#160;31, 2026, up through June&#160;11, 2026, which is the date that
these unaudited condensed consolidated financial statements are issued, unless as disclosed elsewhere, no other material subsequent events
occurred that would require recognition or disclosure in the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001118"
          xlink:label="Fact001118"
          xlink:type="locator"/>
        <link:footnote id="Footnote001253" xlink:label="Footnote001253" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes an aggregate of 321,429
Ordinary Shares cancelled on September&#160;9, 2025 to the extent that the underwriters&#x2019; over-allotment was not exercised.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001118"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001119"
          xlink:label="Fact001119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001119"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1227"
          xlink:label="xdx2ixbrl1227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1227"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001228"
          xlink:label="Fact001228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001228"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001229"
          xlink:label="Fact001229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001229"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1230"
          xlink:label="xdx2ixbrl1230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1230"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001231"
          xlink:label="Fact001231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001231"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1232"
          xlink:label="xdx2ixbrl1232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1232"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002299"
          xlink:label="Fact002299"
          xlink:type="locator"/>
        <link:footnote id="Footnote002330" xlink:label="Footnote002330" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002299"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2301"
          xlink:label="xdx2ixbrl2301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2301"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2303"
          xlink:label="xdx2ixbrl2303"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2303"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002305"
          xlink:label="Fact002305"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002305"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002315"
          xlink:label="Fact002315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002315"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2317"
          xlink:label="xdx2ixbrl2317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2317"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2319"
          xlink:label="xdx2ixbrl2319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2319"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002321"
          xlink:label="Fact002321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002321"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002307"
          xlink:label="Fact002307"
          xlink:type="locator"/>
        <link:footnote id="Footnote002331" xlink:label="Footnote002331" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002307"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2309"
          xlink:label="xdx2ixbrl2309"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2309"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2311"
          xlink:label="xdx2ixbrl2311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2311"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002313"
          xlink:label="Fact002313"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002313"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002323"
          xlink:label="Fact002323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002323"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2325"
          xlink:label="xdx2ixbrl2325"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2325"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2327"
          xlink:label="xdx2ixbrl2327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2327"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002329"
          xlink:label="Fact002329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002329"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002569"
          xlink:label="Fact002569"
          xlink:type="locator"/>
        <link:footnote id="Footnote002584" xlink:label="Footnote002584" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002569"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002571"
          xlink:label="Fact002571"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002571"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002573"
          xlink:label="Fact002573"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002573"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002575"
          xlink:label="Fact002575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002575"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003570"
          xlink:label="Fact003570"
          xlink:type="locator"/>
        <link:footnote id="Footnote003604" xlink:label="Footnote003604" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003570"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3572"
          xlink:label="xdx2ixbrl3572"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3572"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3574"
          xlink:label="xdx2ixbrl3574"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3574"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003576"
          xlink:label="Fact003576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003576"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003589"
          xlink:label="Fact003589"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003589"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3591"
          xlink:label="xdx2ixbrl3591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3591"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3593"
          xlink:label="xdx2ixbrl3593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3593"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003595"
          xlink:label="Fact003595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003595"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003578"
          xlink:label="Fact003578"
          xlink:type="locator"/>
        <link:footnote id="Footnote003605" xlink:label="Footnote003605" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003578"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3580"
          xlink:label="xdx2ixbrl3580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3580"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3582"
          xlink:label="xdx2ixbrl3582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3582"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003584"
          xlink:label="Fact003584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003584"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003597"
          xlink:label="Fact003597"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003597"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3599"
          xlink:label="xdx2ixbrl3599"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3599"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3601"
          xlink:label="xdx2ixbrl3601"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3601"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003603"
          xlink:label="Fact003603"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003603"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003615"
          xlink:label="Fact003615"
          xlink:type="locator"/>
        <link:footnote id="Footnote003630" xlink:label="Footnote003630" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003615"
          xlink:to="Footnote003630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003617"
          xlink:label="Fact003617"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003617"
          xlink:to="Footnote003630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003623"
          xlink:label="Fact003623"
          xlink:type="locator"/>
        <link:footnote id="Footnote003631" xlink:label="Footnote003631" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003623"
          xlink:to="Footnote003631"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003625"
          xlink:label="Fact003625"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003625"
          xlink:to="Footnote003631"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003799"
          xlink:label="Fact003799"
          xlink:type="locator"/>
        <link:footnote id="Footnote003835" xlink:label="Footnote003835" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003799"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003801"
          xlink:label="Fact003801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003801"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003803"
          xlink:label="Fact003803"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003803"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003805"
          xlink:label="Fact003805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003805"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003807"
          xlink:label="Fact003807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003807"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003809"
          xlink:label="Fact003809"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003809"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003811"
          xlink:label="Fact003811"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003811"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003813"
          xlink:label="Fact003813"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003813"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003820"
          xlink:label="Fact003820"
          xlink:type="locator"/>
        <link:footnote id="Footnote003836" xlink:label="Footnote003836" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003820"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003822"
          xlink:label="Fact003822"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003822"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003824"
          xlink:label="Fact003824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003824"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003826"
          xlink:label="Fact003826"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003826"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003828"
          xlink:label="Fact003828"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003828"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003830"
          xlink:label="Fact003830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003830"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003832"
          xlink:label="Fact003832"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003832"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003834"
          xlink:label="Fact003834"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003834"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
